Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM) by Bertoluci, Marcello Casaccia et al.
Bertoluci et al. Diabetol Metab Syndr  (2017) 9:53 
DOI 10.1186/s13098-017-0251-z
REVIEW
Brazilian guidelines on prevention 
of cardiovascular disease in patients 
with diabetes: a position statement from the 
Brazilian Diabetes Society (SBD), the Brazilian 
Cardiology Society (SBC) and the Brazilian 
Endocrinology and Metabolism Society (SBEM)
Marcello Casaccia Bertoluci1,2*, Rodrigo Oliveira Moreira3,4,5, André Faludi6, Maria Cristina Izar7, 
Beatriz D. Schaan8, Cynthia Melissa Valerio3, Marcelo Chiara Bertolami6, Ana Paula Chacra9, 
Marcus Vinicius Bolivar Malachias10, Sérgio Vencio11, José Francisco Kerr Saraiva12, Roberto Betti9, 
Luiz Turatti9, Francisco Antonio Helfenstein Fonseca7, Henrique Tria Bianco7, Marta Sulzbach6, 
Adriana Bertolami6, João Eduardo Nunes Salles13, Alexandre Hohl14, Fábio Trujilho15, Eduardo Gomes Lima9, 
Marcio Hiroshi Miname9, Maria Teresa Zanella18, Rodrigo Lamounier16, João Roberto Sá19, Celso Amodeo6, 
Antonio Carlos Pires17 and Raul D. Santos9
Abstract 
Background: Since the first position statement on diabetes and cardiovascular prevention published in 2014 by the 
Brazilian Diabetes Society, the current view on primary and secondary prevention in diabetes has evolved as a result 
of new approaches on cardiovascular risk stratification, new cholesterol lowering drugs, and new anti-hyperglycemic 
drugs. Importantly, a pattern of risk heterogeneity has emerged, showing that not all diabetic patients are at high or 
very high risk. In fact, most younger patients who have no overt cardiovascular risk factors may be more adequately 
classified as being at intermediate or even low cardiovascular risk. Thus, there is a need for cardiovascular risk stratifica-
tion in patients with diabetes. The present panel reviews the best current evidence and proposes a practical risk-
based approach on treatment for patients with diabetes.
Main body: The Brazilian Diabetes Society, the Brazilian Society of Cardiology, and the Brazilian Endocrinology and 
Metabolism Society gathered to form an expert panel including 28 cardiologists and endocrinologists to review the 
best available evidence and to draft up-to-date an evidence-based guideline with practical recommendations for risk 
stratification and prevention of cardiovascular disease in diabetes. The guideline includes 59 recommendations cover-
ing: (1) the impact of new anti-hyperglycemic drugs and new lipid lowering drugs on cardiovascular risk; (2) a guide 
to statin use, including new definitions of LDL-cholesterol and in non-HDL-cholesterol targets; (3) evaluation of silent 
myocardial ischemia and subclinical atherosclerosis in patients with diabetes; (4) hypertension treatment; and (5) the 
use of antiplatelet therapy.
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Background
Since the first position statement on diabetes and car-
diovascular prevention published in 2014 by the Brazil-
ian Diabetes Society [1], important studies have been 
published in the area of cardiovascular assessment and 
prevention in patients with diabetes [2]. These studies 
have deeply advanced the current view on primary and 
secondary prevention in diabetes, and suggested new 
approaches on cardiovascular risk stratification, new 
cholesterol-lowering drugs, and new anti-hyperglycemic 
drugs with novel significant cardiovascular effects and 
mortality reduction.
To address this challenge, and in recognition of the 
multifaceted nature of disease, the Brazilian Diabetes 
Society joined the Brazilian Society of Cardiology and 
the Brazilian Endocrinology and Metabolism Society 
and gathered an expert panel formed by 28 cardiolo-
gists and endocrinologists to review the best avail-
able evidence and to draft up-to-date evidence-based 
guidelines with practical recommendations on both 
the stratification and prevention of cardiovascular 
disease in diabetes. The main innovations include: (1) 
considerations on the impact of new anti-hyperglyce-
mic drugs and new lipid-lowering drugs on cardiovas-
cular risk; (2) a practical risk factor-based approach 
to guide statin use, including new definitions of LDL-
cholesterol and non-HDL-cholesterol targets; (3) 
an evidence-based approach to evaluate silent myo-
cardial ischemia and subclinical atherosclerosis in 
patients with diabetes; (4) the best current approaches 
for treating hypertension; and (5) recommendation 
updates for the use of antiplatelet therapy. We hope 
these guidelines will help clinicians to improve the 
quality of the care provided to patients with diabetes.
Methods
Initially, the panel members were divided into seven sub-
committees to define the main topics requiring an updated 
position from the societies. Panel members searched PUB-
MED for randomized clinical trials and meta-analyses of 
clinical trials, and observational studies of good quality 
published from 1997 to 2017 using MeSH terms: [dia-
betes], [type 2 diabetes], [cardiovascular disease], [car-
diovascular risk stratification] [coronary artery disease], 
[screening], [silent ischemia], [statins], [hypertension], 
[acetyl salicylic acid]. Low quality observational studies, 
meta-analyses with high heterogeneity and cross-sectional 
studies were not included although they might have influ-
enced the level of evidence indicated. Expert opinion was 
used when the results of the search were not satisfactory 
for a specific item. It is important to note that it was not 
the aim of this position statement to include a rigorous 
systematic review.
A preliminary manuscript outlining recommenda-
tion grades and levels of evidence (Table  1) was then 
drafted. This step took several rounds of discussion 
among subcommittee members, who reviewed the find-
ings and made new suggestions. The manuscript was 
Conclusions: Diabetes is a heterogeneous disease. Although cardiovascular risk is increased in most patients, those 
without risk factors or evidence of sub-clinical atherosclerosis are at a lower risk. Optimal management must rely on 
an approach that will cover both cardiovascular disease prevention in individuals in the highest risk as well as protec-
tion from overtreatment in those at lower risk. Thus, cardiovascular prevention strategies should be individualized 
according to cardiovascular risk while intensification of treatment should focus on those at higher risk.
Keywords: Diabetes mellitus, Cardiovascular prevention, Cardiovascular screening, Blood glucose, Risk factors, 
Coronary artery disease, Dyslipidemias, Hypertension, Antiplatelet agents
Table 1 Recommendation grades and levels of evidence
Grade of recommendation
 Class I Evidence is conclusive or, if not, there is a general consensus that a procedure or a treatment is safe and efficacious
 Class II There is conflicting evidence or divergent opinion on safety, efficacy or utility of treatment or procedure
 Class IIa Opinions are in favor of the treatment or procedure. The majority of experts approves
 Class IIb Less well established efficacy, opinions are divergent
 Class III There is evidence or consensus that the treatment or procedure is not useful, efficacious or may be harmful
Levels of evidence
 A Multiple concordant well designed randomized clinical trials or robust meta-analyses of randomized clinical trials
 B Data from less robust meta-analyses, a single randomized clinical trial or observational studies
 C Expert opinion
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then returned to the lead author in charge of text harmo-
nization and inclusion of minor changes, and was subse-
quently submitted to further view rounds by committee 
members, seeking a consensus position. After this phase, 
the manuscript was forwarded to the editorial board for 
final editing and submitting for publication.
These guidelines were divided into seven modules, 
namely:
Cardiovascular risk
Module 1: Cardiovascular risk stratification
Module 2: Screening of subclinical atherosclerosis
Module 3: Screening of silent myocardial ischemia
Cardiovascular prevention
Module 4: Management of hyperglycemia
Module 5: Management of dyslipidemia
Module 6: Management of hypertension
Module 7: Antiplatelet therapy
Module 1: Cardiovascular risk stratification
Patients with type 1 and 2 diabetes are divided into four 
broad cardiovascular risk categories—LOW, INTERME-
DIATE, HIGH, AND VERY HIGH (Table  2)—based on 
age, presence of stratifying risk factors (SF) (Table  3), 
subclinical atherosclerosis (SCAT) (Table  4), or clinical 
atherosclerotic disease (CLAD) (Table  5). The 10-year 
cardiovascular event rate for low, intermediate, high, and 
very high risk categories were respectively: <10, 10–20, 
20–30, and >30% (Table 2).   
The LOW and INTERMEDIATE risk categories are 
based solely on age and SF (Table  3). SCAT (Table  4), 
and CLAD (Table 5) are not present in these risk groups. 
As seen in a large Ontario population-based retrospec-
tive cohort study, 379,003 individuals with diabetes 
were included and followed up for a mean of 8  years 
until the occurrence of a first acute myocardial infarc-
tion or death from all causes [3]. The transition from 
LOW to INTERMEDIATE RISK occurred at ages 38 and 
46 years respectively for men and women. The transition 
from INTERMEDIATE to HIGH-RISK status occurred 
Table 2 Cardiovascular risk categories in patients with diabetes
Risk category CHD event rate in 10 years (%) Age Condition
LOW <10
Men < 38 years
Women < 46 years
No stratification factors (SF)a
No subclinical atherosclerosis (SCAT)b
No clinical atherosclerotic disease (CLAD)cINTERMEDIATE 10–20
Men 38–49 years
Women 46–56 years
HIGH 20–30
Men > 49 years
Women >56 years or any 
age if SFa or SCATb
Stratification factors (SF)a
Subclinical atherosclerosis (SCAT)b
No clinical atherosclerotic disease (CLAD)c
VERY HIGH >30 Any age if CLADc Clinical atherosclerotic disease (CLAD)c
a Stratification factors (Table 3)
b Subclinical atherosclerosis (Table 4)
c Clinical atherosclerotic disease (Table 5)
Table 3 Stratifying risk factors (SF)
a Valid for patients in whom the onset of diabetes occurred after 18 years of age
b Family history of premature coronary heart disease is defined as the presence 
of coronary events in first-degree relatives (father, mother, or siblings) when 
occurring before 55 years of age in men or before 65 years of age in women
c The IDF definition of Metabolic Syndrome consists of: (1) abdominal 
circumference >90 cm for men and >80 cm for women, plus; (2) triglycerides 
>150 mg/dL for both men and women; (3) HDL-c < 40 mg/dL in men and 
<50 mg/dL in women; (4) blood pressure ≥130/85 mmHg or treatment for 
hypertension; and (5) a fasting blood glucose ≥100 mg/dL
d Current smoking is defined when the last smoking episode occurred less than 
1 year before the time of stratification
Age >49 years in men or >56 years in women [3]
Duration of diabetes greater than 10 years [4]a
Family history of premature coronary heart disease [5]b
Presence of IDF-defined Metabolic Syndrome [6]c
Treated or untreated hypertension [7]
Current smoking [8]d
Estimated glomerular filtration rate below 60 mL/min/1.73 m2 [9]
Albuminuria above 30 mg/g of creatinine [10]
Cardiac autonomic neuropathy [11]
Diabetic retinopathy [12, 13]
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respectively at ages: 49 and 56, for both men and women 
[3]. Therefore, patients with diabetes without clinical or 
subclinical cardiovascular disease and risk factors are 
considered at INTERMEDIATE RISK when aged are 
38–49 years (men) or 46–56 years (women), and at LOW 
RISK if they are younger.
The HIGH-RISK group is defined by the presence, at 
any age, of at least one SF (Table 3) or one indicator of 
SCAT (Table 4), in the absence of CLAD (Table 5). Even 
in the absence of these conditions, a patient with diabe-
tes is also considered at HIGH RISK when age is above 
49 years in men or 56 years in women. Finally, the VERY 
HIGH-RISK group includes patients who, at any age, 
have CLAD as defined in Table 5.
Module 2: Screening of subclinical atherosclerosis
1. Coronary artery calcification (CAC) score is associated 
with cardiovascular events and mortality in patients 
with diabetes [I, A]
Summary of evidence
  • Coronary artery calcification (CAC) is a marker for 
the presence and burden of atherosclerosis, as dem-
onstrated in anatomical studies [22]. The MESA [23] 
and Heinz Nixdorf [24] studies demonstrated that 
CAC is a predictor of coronary events and is use-
ful for stratification of cardiovascular risk among 
patients in primary prevention. This is also true for 
patients with diabetes: the higher the CAC score, the 
higher the risk of cardiovascular events in subjects 
with diabetes [25].
  • Raggi et al. [26] followed 10,377 asymptomatic indi-
viduals (903 with diabetes), who had been investi-
gated with CAC at baseline, for a mean of 5  years. 
The mean CAC score was higher in patients with dia-
betes than in patients without diabetes (281 ± 567 vs. 
119 ± 341, p < 0.0001). This study also showed that a 
higher CAC score was associated with a higher mor-
tality rate, especially in patients with diabetes. How-
ever, the survival rate was similar to that observed in 
patients with and without diabetes (98.8% vs. 99.4% 
respectively, p = 0.5) when CAC was zero.
  • The PREDICT study [27] followed 589 patients with 
diabetes without cardiovascular disease (mean age 
63.1  years) for a median of 4  years. The greater the 
coronary calcium score, the greater the risk of cardi-
ovascular outcomes. The area under the ROC curve 
(AUC-ROC) for risk determination using the UKPDS 
risk score was 0.63, and was increased to 0.73 when 
CAC was included (p = 0.03).
2. Coronary artery calcium score (CAC score) determination 
has the best net reclassification rate compared to other 
risk markers when added to clinical global risk score 
calculators alone. This can be especially useful to reclassify 
patients at INTERMEDIATE risk to higher or lower‑risk 
categories. However, this Panel recognizes that, despite its 
utility, CAC score may not be easy to obtain in a large 
proportion of patients [IIa, B]
Summary of evidence
  • In a large cohort study of 44,052 asymptomatic indi-
viduals referred for CAC testing, including 2384 
with diabetes [28], the authors showed that car-
diovascular risk was more accurately stratified with 
CAC in patients with diabetes. Patients in the low 
and moderate risk categories had a mortality rate of 
39.4 deaths/1000/year when CAC was above 100. 
Conversely, those classified in the clinical high-risk 
category with no calcium present (CAC =  0) had a 
10-year mortality rate of 6.59 deaths/1000/year. In 
the lower-risk subgroup (<5% in 10  years), 18% had 
CAC > 100, while in the higher risk category (>20% 
in 10 years), 16% had CAC = 0. In other words, CAC 
was able to reclassify a considerable number of low-
risk patients into a high-risk category [27]. A CAC 
score >0 was present in 57.3% of patients in the low-
risk category and in 70.6% of those in intermediate-
risk categories.
  • The prospective, community-based coronary artery 
risk development in young adults (CARDIA) study 
[29] recruited 5115 participants aged 18–30  years, 
with CAC measured at 15, 20, and 25  years after 
recruitment. The main outcomes were incident coro-
nary heart disease, including fatal and nonfatal myo-
Table 4 Subclinical atherosclerosis (SCAT)
a When available, CAC scoring should be the preferred modality
b CCTA should not be performed routinely in truly asymptomatic patients
c Patients suffering from an AAA are at elevated risk of cardiovascular morbidity 
and mortality, due to common risk factors and comorbidities associated with 
the aneurysm
Coronary artery calcium score (CAC) >10 U  Agatstona
Carotid plaque (intima-media thickness >1.5 mm) [14]
Computed tomography coronary angiography (CCTA) with a definite 
plaque [15]b
Ankle-brachial index <0.9 [16]
Abdominal aortic aneurysm (AAA) [17–21]c
Table 5 Clinical atherosclerotic disease (CLAD)
Acute coronary syndrome:
 Acute myocardial infarction or unstable angina
Stable angina or previous acute myocardial infarction
Atherothrombotic stroke or transient ischemic attack
Coronary, carotid, or peripheral revascularization
Peripheral vascular insufficiency or limb amputation
Severe atherosclerotic disease (stenosis >50%) in any vascular territory
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cardial infarction, acute coronary syndrome without 
myocardial infarction, coronary revascularization, 
or CHD death. The probability of developing CAC 
by age 32–56 was estimated using clinical risk fac-
tors measured 7 years apart between ages 18 and 38. 
Participants were followed up for 12.5 years, with 57 
incident CHD events and 108 incident CVD events 
observed. After adjusting for risk factors and treat-
ments, those with any CAC had a fivefold increase in 
CHD events (hazard ratio [HR] 5.0, 95% CI 2.8–8.7) 
and a threefold increase in CVD events (HR 3.0, 95% 
CI 1.9–4.7). Within CAC score strata of 1–19, 20–99, 
and >100, the HRs for CHD were 2.6 (95% CI 1.0–
5.7), 5.8 (95% CI 2.6–12.1), and 9.8 (95% CI 4.5–20.5), 
respectively. A CAC score ≥100 was associated with 
an incidence of 22.4 deaths per 100 participants in 
12.5 years (HR 3.7, 95% CI 1.5–10.0). The presence of 
CAC among individuals aged 32–46 was associated 
with increased risk of fatal and nonfatal CHD dur-
ing 12.5 years of follow-up. Thus, screening for CAC 
might be considered in individuals with risk factors 
in early adulthood to inform discussions about pri-
mary prevention.
  • The MESA study was a prospective population-
based cohort that investigated the prevalence and 
progression of subclinical cardiovascular disease in 
persons without cardiovascular disease at baseline, 
including 6814 men and women aged 45–84  years 
and 9.8% with diabetes, to assess the predictive accu-
racy and improvement in reclassification gained 
by the addition of CAC score (among others) over 
the atherosclerotic cardiovascular risk estimator 
(ASCVD). The authors concluded that CAC score 
had a modestly improved discriminative ability over 
ASCVD. The Harrell’s C statistic difference was sig-
nificant (0.74 vs. 0.76, p  =  0.04), and CAC score 
addition was the only marker that improved ASCVD 
risk score [30].
3. In patients with diabetes, a CAC score >10 is an indicator 
of increased mortality and future cardiovascular events. 
It is recommended that patients with diabetes with a CAC 
score >10 should be considered as HIGH RISK. [I, A]
Summary of evidence
  • In a meta-analysis of eight studies including 6521 
patients with diabetes [31], with a mean follow up 
of 5.18 years, the relative risk of the composite out-
come of all-cause mortality and/or cardiovascular 
events with CAC > 10 vs. CAC < 10 was 5.47 (95% CI 
2.59–11.53, p  <  0.001) [31]. Nevertheless, it should 
be noted that significant heterogeneity was detected 
across studies  (I2 = 82.4%, p < 0.001). CAC > 10 had 
a sensitivity of 94% and a specificity of 34% for the 
composite outcome. A higher CAC score entailed 
lower sensitivity and higher specificity. For example, 
when comparing CAC  <  10 vs. CAC  >  1000, sensi-
tivity dropped to 90%, while specificity increased to 
74%. For an individual with diabetes and CAC < 10, 
post-test probability for the composite outcome was 
1.8%, representing a 6.8-fold decrease in the pretest 
probability of a CVD outcome. The study concluded 
that a CAC < 10 is helpful to detect lower-risk indi-
viduals in this population.
  • The Diabetes Heart Study monitored cardiovascu-
lar mortality in 1051 patients with diabetes followed 
for 7.4  years. A positive association was observed 
between CAC and mortality in the model adjusted 
for age, sex, race, smoking, and LDL-C. Using the 
group score of 0–9 for CAC as a reference, the 
study found the following relative risks according to 
CAC severity: CAC 10–99: 1.40 (95% CI 0.57–3.74, 
p  =  0.47); CAC 100–299: 2.87 (95% CI 1.17–7.77, 
p  =  0.02); CAC 300–999: 3.04 (95% CI 1.32–7.90, 
p  =  0.008); and CAC  ≥  1000: 6.71 (95% CI 3.09–
16.87, p  =  0.0001) [32]. Later in 2013, the same 
authors published an analysis of CAC score com-
pared to traditional risk factors to predict cardiovas-
cular mortality. CAC improved the AUC-ROC from 
0.70 (95% CI 0.67–0.73) to 0.75 (95% CI 0.72–0.78). 
The net reclassification index (NRI) in the moder-
ate-risk group (7–20% in 10  years) was 0.34, which 
means that 34% of individuals were reclassified into 
different risk categories [33].
4. CAC score outperforms carotid‑artery intima‑media 
thickness (CIMT) and ankle‑brachial index (ABI) 
to discriminate and reclassify cardiovascular risk, at least 
in nondiabetic subjects. [IIa, B]
Summary of evidence
  • The MESA study compared the performance of dis-
tinct stratification methods in an intermediate-risk 
population with no previous cardiovascular event 
(estimated Framingham risk score between 5 and 20%) 
[33]. In that study, calcium score (AUC for CAC plus 
Framingham risk score: 0.784) presented better risk 
discrimination compared to CIMT (AUC for CIMT 
plus Framingham risk score: 0.652) and ABI (AUC 
for ABI plus Framingham risk score: 0.650), as well as 
better reclassification ability (NRI for calcium score: 
0.659; NRI for CIMT: 0.102; NRI for ABI: 0.036) [33]. 
Although patients with diabetes mellitus were not part 
of the study, calcium score was shown to be clearly 
superior to CIMT and ABI to predict risk of coronary 
events.
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5. Carotid plaque can predict major adverse cardiovascular 
events (MACE) and reclassify risk. Adding plaque 
information with abnormal wall thickness (CIMT > 1.5 mm) 
may be useful to reclassify intermediate risk into high risk. 
[IIb, B]
Summary of evidence
  • The Atherosclerosis Risk in Communities (ARIC) 
study followed 13,145 individuals without previous 
CVD (57% women, age: 54.0 ±  8.5 years, 10% with 
diabetes) for a mean of 15.1  years, during which 
1812 CHD events occurred [34]. CIMT (catego-
rized as <25th percentile, 25th–75th percentile or 
>75th percentile for sex) or plaque presence, defined 
in the presence of at least 2 of 3 criteria—abnor-
mal wall thickness (CIMT  >  1.5  mm), abnormal 
shape (protrusion into the lumen, loss of alignment 
with adjacent arterial wall boundary), and abnor-
mal wall texture (brighter echoes than adjacent 
boundaries)—were superior for risk discrimination 
and reclassification in comparison with risk factors 
alone. According to the authors, when plaque infor-
mation (abnormal wall thickness) and CIMT were 
considered in addition to risk factors, 8.6, 37.5, 38.3, 
and 21.5% of the overall sample were reclassified in 
the <5, 5–10, 10–20, and >20% 10-year estimated 
risk groups respectively. Adding plaque and CIMT 
reclassified 17.4, 32.8, 36.6, and 25.2% of the men 
and 5.1, 40.2, 38.4, and 24.9% of the women in the 
same risk groups.
  • The prospective cohort BioImage Study enrolled 
5808 asymptomatic adults without previous car-
diovascular events to evaluate the role of vascular 
imaging in cardiovascular risk prediction [35]. All 
patients were evaluated for carotid plaque burden 
score based on a novel 3-dimensional carotid ultra-
sound and CAC score at baseline, and followed up 
for a median of 2.7 years. The main study outcome 
was the presence of MACE defined as cardiovas-
cular death, myocardial infarction, and ischemic 
stroke. The authors analyzed the carotid plaque bur-
den (cPB) through the sum of the areas of carotid 
plaques as seen along both carotid arteries and their 
ramifications. cPB was analyzed in tertiles. After 
adjustments for risk factors, and compared with 
individuals without any cPB, hazard ratios (HR) 
for MACE at tertiles 1, 2, and 3 were 0.78 (95% CI 
0.31–1.91), 1.45 (95% CI 0.67–3.14), and 2.36 (95% 
CI 1.13–4.92) respectively. The net reclassification 
index (NRI) significantly improved in 23%. Thus, 
detection of subclinical carotid atherosclerosis 
improves risk prediction and reclassification com-
pared with traditional risk factors [35].
Module 3: Screening of silent myocardial ischemia
6. A resting electrocardiogram (ECG) should be considered 
at least annually in asymptomatic patients with diabetes 
at INTERMEDIATE, HIGH, and VERY HIGH RISK. [IIa, B]
Summary of evidence
  • On the basis of expert-opinion evidence, an annual 
resting ECG is recommended for diabetic patients at 
high and very high cardiovascular risk, given its low 
cost, high safety, and prognostic value of ECG abnor-
malities, which must lead to further exploration.
  • In the Epidemiology of Diabetes Interventions and 
Complications (EDIC) Study [36], patients with type 
1 diabetes had a mean follow-up of 19  years and 
underwent at least one ECG annually. The presence 
of any major ECG abnormalities was associated with 
a more than twofold increased risk of CVD events 
(hazard ratio [HR] 2.10 [95% CI 1.26–3.48] vs. no 
abnormality/normal ECG, and 2.19 [95% CI 1.46–
3.29] vs. no major abnormality).
  • In the United Kingdom Prospective Diabetes Study 
(UKPDS), one in every six newly diagnosed patients 
with diabetes had ECG evidence of silent myocardial 
infarction [37].
  • The MiSAD study [38] included 925 asymptomatic 
intermediate to high-risk patients with type 2 dia-
betes mellitus who underwent an ECG stress test, 
which, if positive, led to stress myocardial perfusion 
imaging (MPI). The prevalence of coronary artery 
disease (CAD) was 12.5% (abnormal exercise test). 
Of individuals with CAD, 6.4% had abnormal per-
fusion at MPI. Multivariate analysis showed that, in 
the overall population, the associated independent 
risk factors were age, total cholesterol, proteinu-
ria, and, importantly, ST-T abnormalities on rest-
ing ECG, which had the highest odds ratio (9.27, CI 
4.44–19.38) and was the only risk factor identified 
in both women and men. Abnormal MPI predicted 
cardiac events at 5  years (HR 5.5, 95% CI 2.4–12.3, 
p  <  0.001). The relevance of ST-T abnormalities on 
resting ECG as a predictor of silent CAD highlights 
the importance of performing periodic resting ECGs 
in patients with type 2 diabetes.
7. Universal screening for coronary artery disease 
with stress induction of myocardial ischemia does not 
improve outcomes and is NOT RECOMMENDED in truly 
asymptomatic diabetic patients when in the absence 
of resting ECG abnormalities, even in the presence of a 
high‑risk condition for cardiovascular events. [III, A]
Summary of evidence
  • The detection of ischemia in asymptomatic diabet-
ics (DIAD) multicenter randomized trial evaluated 
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whether detection of silent myocardial ischemia in 
asymptomatic patients with diabetes could reduce 
cardiovascular events. The participants were rand-
omized to undergo routine screening for detection 
of silent ischemia using adenosine stress myocardial 
perfusion single-photon emission computed tomog-
raphy (SPECT) or no screening. A total of 1123 
asymptomatic diabetic patients were randomized. 
After a mean follow-up of 4.8  years, a non-signifi-
cant reduction in the overall cardiac event rate was 
detected in the screened vs. unscreened group, with 
HR of 0.88 (95% CI 0.44–1.88) [39].
  • A prospective, multicenter randomized trial—do you 
need to assess myocardial ischemia in type-2 diabe-
tes (DYNAMIT) study [40]—evaluated screening for 
silent myocardial ischemia using a bicycle exercise 
test or dipyridamole stress SPECT in 631 asympto-
matic diabetic patients with no evidence of coronary 
artery disease. The study was discontinued prema-
turely because of difficulties in recruitment and a 
lower-than-expected event rate. There were no sig-
nificant differences between the screening and usual-
care groups for the main outcome (HR 1.00, 95% CI 
0.59–1.71). A meta-analysis of the DYNAMIT and 
DIAD trials [39] produced similar results, with nar-
rower confidence intervals for each endpoint.
  • The BARDOT trial [41] was a prospective multi-
center study evaluating the prevalence, progression, 
treatment, and outcome of silent coronary artery 
disease (CAD) in 400 asymptomatic patients with 
diabetes at high coronary risk, without history or 
symptoms of CAD. Patients underwent myocardial 
perfusion SPECT (MPS) at baseline and after 2 years 
[41]. Patients with normal MPS received usual care, 
while those with abnormal MPS received medical 
or combined invasive and medical management. An 
abnormal MPS was found in 22% of patients. Nor-
mal-MPS patients had a low rate of first manifesta-
tions of CAD compared with patients with abnor-
mal MPS at baseline. Patients with normal MPS had 
2-year rates of MACE, cardiac death, and of new 
ischemia or new scar of 2.9, 0.7, and 3.2% respec-
tively. Patients with abnormal MPS had a sevenfold 
higher rate of progression to “overt CAD,” independ-
ent of therapy [41]. However, although the BAR-
DOT trial results suggested screening and treating 
high-risk patients on the basis of MPS, it is impor-
tant to note that only about 20% of patients with an 
abnormal MPS would be advised to receive anti-
ischemic therapy. The findings of the Bardot study 
are preliminary and still require confirmation. A 
combined medical and invasive strategy may reduce 
scintigraphic but not symptomatic CAD progression 
compared with medical therapy alone. Thus, univer-
sal screening cannot be currently advised in high-risk 
patients until more robust data are available.
8. Consider investigation for myocardial ischemia 
in asymptomatic patients with diabetes when resting 
ECG abnormalities are present and in patients who 
exhibit typical or atypical cardiac symptoms (unexplained 
dyspnea, atypical chest pain or discomfort), evidence 
of associated vascular disease (carotid bruits, transient 
ischemic attack, stroke, peripheral arterial disease) and a 
very high CAC score (>400), when available. [IIa, B]
Summary of evidence
  • In a sub-study of the 30-year UKPDS [37], data from 5102 
diabetic patients were analyzed through Cox propor-
tional hazards regression to examine outcomes by silent 
myocardial ischemia (SMI) status. Of 1967 patients 
with complete baseline data, 326 (16.6%) had ECG evi-
dence of SMI at enrollment. Around one in six UKPDS 
patients with newly-diagnosed T2D had evidence of 
SMI, which was independently associated with an 
increased risk of fatal MI and all-cause mortality.
  • Raggi et  al. [26] conducted a 5-year follow-up of 
10,377 asymptomatic individuals (903 with diabe-
tes) with a baseline CAC score available. The authors 
used Cox proportional hazard models, with and 
without adjustment for other risk factors, to pre-
dict all-cause mortality as the primary endpoint. 
All-cause mortality was increased in asymptomatic 
patients with diabetes in proportion to the screen-
ing CAC. In a risk-adjusted model, there was signifi-
cant interaction of CAC with diabetes (p < 0.00001), 
indicating that for every increase in CAC, there was 
a greater increase in mortality for diabetic compared 
to nondiabetic subjects. The mortality of diabetic 
patients with CAC  >  400 in the study was around 
10% in 4–5 years, greater than that of nondiabetics.
9. Exercise ECG should be considered as the initial test 
for investigation of ischemia in most symptomatic 
patients. Exceptions are when resting ECG abnormalities 
preclude interpretation of exercise stress testing and in 
patients who are unable to exercise. In those cases, 
pharmacological stress echocardiography, myocardial 
perfusion imaging (MPI), coronary computed tomography 
angiography (CCTA), and stress perfusion cardiac magnetic 
resonance imaging are reasonable options. [IIa, C]
Summary of evidence
  • The treadmill stress test is widely used for CAD 
detection in the general population because it is eas-
ily performed, has relatively good predictive value, 
and is inexpensive. In diabetic patients, the negative 
predictive value of the stress ECG is 87%, with 75% 
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specificity. Lyerly et  al. [42] studied 2854 men with 
documented diabetes mellitus (mean age 49.5 years) 
who completed a maximal treadmill exercise test 
with a mean follow-up of 16 years. Those with nor-
mal ECG presented the highest CHD-free survival. 
Those with abnormal ECG and those who were 
unable to perform maximal exercise had lower CHD-
free survival rates. Stress SPECT with thallium or 
MIBI provides a wide range of information, including 
ischemia location and extension and left ventricular 
function, helping physicians appreciate the severity 
of CAD. This modality can be coupled with pharma-
cologic agents (dipyridamole, adenosine) for stress 
induction. In individuals with diabetes, SPECT has 
higher sensitivity (80–90%) and specificity (75–90%) 
than the ECG stress test [43]. Another alternative for 
SMI screening is stress echocardiography using exer-
cise or drugs such as dobutamine. Stress echocardi-
ography detects wall motion abnormalities during 
stress and provides information on ischemia intensity 
and left ventricular function. Sensitivity and speci-
ficity are 81 and 85% respectively in asymptomatic 
diabetic patients [44]. CMRI perfusion imaging, with 
sensitivity of 86.5% and specificity of 83.4% to detect 
angiographically significant coronary stenosis (>50% 
left main coronary artery or >70% branch disease), is 
an alternative for patients who cannot exercise [45].
10. Coronary computed tomography angiography 
(CCTA) should NOT be used routinely in ASYMPTOMATIC 
patients with diabetes, since it does not seem to reduce 
cardiovascular event risk when used for risk stratification 
of this population. [III, B]
Summary of evidence
  • The FACTOR 64 study [46] evaluated whether 
CCTA was beneficial to reduce clinical outcomes 
in asymptomatic patients with type 1 or 2 diabe-
tes. Patients with diabetes were included if disease 
duration was at least 5  years. The patients were 
randomly assigned to CCTA or optimal diabetes 
care, and the result of CCTA was used for clinical 
decision-making. Non-screening patients received 
standard-of-care treatment for existing risk factors, 
and physicians were encouraged to reach therapeu-
tic goals in accordance with current guidelines (gly-
cated hemoglobin <7.0%, LDL-c  <  100  mg/dL, sys-
tolic blood pressure  <  130  mmHg). Patients in the 
screening CCTA arm with normal coronary arteries 
remained on standard-of-care therapy. Patients who 
exhibited mild or severe proximal lesions or distal 
lesions or a CAC score >10 were advised to pursue 
more aggressive treatment targets (LDL-c  <  70  mg/
dL, HDL-c  >  50  mg/dL, triglycerides <150  mg/
dL, glycated hemoglobin <6.0%, and systolic blood 
pressure <120  mmHg). Patients with severe steno-
sis underwent invasive coronary angiography, and 
the decision regarding revascularization was based 
on the judgment of the assistant physician. Patients 
with moderate lesions underwent evaluation of 
myocardial ischemia. Nine hundred patients were 
randomized, 452 to CCTA, with a mean follow-up 
of 4  years. Mean duration of diabetes in the group 
not undergoing CCTA was 13.5 years, vs. 12.3 years 
in the CCTA arm. The primary endpoint rate (total 
mortality, nonfatal MI, or unstable angina) was simi-
lar, with 28 events (6.2%) in the CCTA group vs. 34 
events (7.6%) in the control group (HR 0.80, 95% CI 
0.49–1.32, p =  0.38). No differences were observed 
for the secondary endpoint (major ischemic cardio-
vascular events). In fact, the observed event rate was 
lower than expected for the sample size, which may 
explain the negative results. Patients with diabetes in 
whom risk factors were well controlled did not ben-
efit from CCTA screening as a preventive measure to 
reduce cardiovascular event risk. Thus, CCTA can-
not be recommended for screening of asymptomatic 
patients with diabetes at this time.
11. In patients at LOW or INTERMEDIATE risk categories, 
with atypical symptoms, coronary computed tomography 
angiography (CCTA) may be considered to rule 
out myocardial ischemia, as it has a good negative 
predictive value. [IIb, B]
Summary of evidence
  • Hadamitzky et  al. [47] evaluated the role of CCTA for 
prediction of cardiovascular events in 140 subjects 
with diabetes and 1782 without diabetes followed for 
a mean of 33  months. Participants presented with 
atypical symptoms of CHD or other risk factors. Those 
with diabetes and a high plaque burden, as character-
ized by high number of coronary segments with ather-
osclerotic plaque (calcified or not), had a much higher 
event rate than those without diabetes (1.8% vs. 0.5% 
per year). Plaque burden was the best marker of coro-
nary events, even when adjusted for calcium score.
Module 4: Management of hyperglycemia
Targets
12. In non‑pregnant adult patients with type 1 or 2 
diabetes mellitus, and in the absence of severe cognitive 
impairment or reduced life expectancy, the recommended 
target for glycemic control is a HbA1c below 7.0%. [I, A]
Summary of evidence
  • The diabetes control and complications trial (DCCT) 
[48] and the United Kingdom Prospective Diabetes 
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Study (UKPDS) [49] demonstrated that achieving an 
HbA1c below 7% reduces microvascular complica-
tions in type 1 and type 2 diabetes. In subjects with 
type 1 diabetes, implementing intensive glycemic con-
trol targeting an HbA1c below 7% in the first 6 years 
of diabetes can promote a 57% reduction in nonfatal 
myocardial infarction, stroke, and death from cardio-
vascular disease on long-term follow-up (9 years), as 
seen in the DCCT/EDIC study [50, 51]. Similarly, in 
type 2 diabetes, intensive glycemic control decreases 
cardiovascular outcomes in the long term (after 
10  years) when implemented in recently diagnosed 
patients [52].
  • Lower HbA1c targets were evaluated in three rand-
omized clinical trials: action to control cardiovascu-
lar risk in diabetes (ACCORD) [53], action in diabetes 
and vascular disease: preterax and diamicron modi-
fied release controlled evaluation (ADVANCE) [54], 
and the veterans affairs diabetes trial (VADT) [55]). 
These trials did not detect reduction in cardiovascular 
outcomes when intensive control (HbA1c < 6.5%) was 
implemented. The ADVANCE study (n  =  11,140), 
ACCORD (n = 10,251), and VADT (n = 1791) evalu-
ated patients with type 2 diabetes and previous car-
diovascular disease or risk factors and diabetes (mean 
duration 8–11.5  years), assessing incidence of car-
diovascular disease after intensive vs. conventional 
treatment. The final mean HbA1c was 6.5 vs. 7.3% 
(ADVANCE), 6.4 vs. 7.5% (ACCORD), and 6.9 vs. 
8.4% (VADT). In the ACCORD trial, but not in the 
other studies, a 22% increase in all-cause mortality 
followed intensive treatment.
13. Less stringent HbA1c targets (below 8.0%) are 
reasonable in patients with known history of severe 
and frequent hypoglycemic events, long‑standing disease, 
short life expectancy, major comorbidities, and established 
vascular complications, as well as in less motivated, 
non‑adherent patients and in those with diminished 
self‑care capacity, limited resources, and a limited support 
system. [IIa, B]
Summary of evidence
  • Tight glucose control may be harmful in many 
patients, particularly the elderly and those with other 
illnesses, especially cardiovascular diseases [56]. 
Intensive glycemic control does not lead to improved 
microvascular outcomes for at least 8  years. Data 
from randomized controlled trials suggest that inten-
sive glycemic control immediately increases the risk 
of severe hypoglycemia 1.5- to 3-fold [57].
  • Observational data from emergency admissions 
showed a consistent increase in severe hypoglyce-
mia over one decade, especially in type 2 diabetes 
patients with lower HbA1c, more comedication, and 
more concomitant diseases [58, 59]. Hypoglycemia 
in these patients has been associated with increased 
mortality, higher risk of dementia, falls, fall-related 
fractures, cardiovascular events, and poor quality of 
life [60]. Mechanisms by which acute hypoglycemia 
may trigger ischemia, arrhythmia, and cardiovas-
cular events include increases in epinephrine and 
norepinephrine levels, which may induce increased 
cardiac rate and/or contractility, thus heightening 
myocardial oxygen consumption, while also pre-
cipitating vasoconstriction and platelet aggregation. 
Moreover, acute hypoglycemia in the presence of 
hypokalemia prolongs cardiac repolarization and 
increases the QT interval, favoring a proarrhythmic 
state [60].
  • In patients with diabetes from a Brazilian multicenter 
registry followed for 12  months, failure to reach 
HbA1c targets  was associated with poorer event-
free survival (all-cause mortality, nonfatal cardiac 
arrest, myocardial infarction, or stroke) as compared 
to good metabolic control (p < 0.041). In that study, 
HbA1c targets of 8.0 and 7.0% were considered in 
patients without a previous cardiovascular event vs. 
those with a previous cardiovascular event [61].
  • Patients with limited resources and a limited support 
system, those with lower motivation, non-adherent 
patients, and those with diminished self-care capac-
ity are not candidates for strict glucose control, as the 
risk of hypoglycemia tends to be higher [62].
  • Considering the high risk of hypoglycemia with 
strict metabolic control, especially in elderly 
patients and in those in which this adverse effect 
may be more harmful, individualized targets 
should be pursued in patients with a known his-
tory of severe and frequent hypoglycemic events, 
longstanding disease, short life expectancy, major 
comorbidities, and established vascular complica-
tions [63]. Considering these data and the results of 
observational studies, the harms associated with an 
HbA1c target lower than 7.5% or higher than 9% are 
likely to outweigh the benefits in most adults older 
than 65 years [57, 64].
  • Data to guide this type of individualized treatment 
are derived from weak evidence. However, the high 
frequency of risk factors for hypoglycemia and its 
adverse impact, as well as the marginal benefits of 
tight control in individuals with short life expectancy, 
suggest a need to reduce overtreatment, particularly 
among the elderly and the other groups cited above 
[56, 60, 64].
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Hospitalized patients
14. In hospitalized patients with acute myocardial 
infarction, it is recommended that blood glucose be 
maintained in the 130–200 mg/dL range by continuous 
intravenous insulin infusion, followed by good long‑term 
metabolic control. [I, B]
Summary of evidence
  • The DIGAMI [65] study included 620 patients with 
diabetes and acute myocardial infarction (AMI) and 
used the following strategies: IV infusion of insulin 
and glucose in the first 24  h with a glycemic target 
of 126–196  mg/dL, subcutaneous administration of 
insulin four times daily for 3  months, vs. standard 
insulin therapy as clinically indicated at the time of 
the study. Treatment with insulin in the acute phase 
produced better glycemic control during hospitaliza-
tion, at 3 months and at 1 year, as well as lower mor-
tality rates at 1 and 3.4 years of follow-up.
  • In the DIGAMI-2 trial [66], use of insulin during 
hospitalization and after discharge was compared to 
insulin therapy only during hospitalization and usual 
treatment throughout the period. Glycemic control 
and cardiovascular outcomes were similar in the two 
groups.
  • In the HI-5 study [67], 240 patients with diabetes 
and glucose ≥140  mg/dL were included at hospital 
admission for AMI and randomized to strict glyce-
mic control (target glycemia 72–180  mg/dL) with 
insulin plus intravenous glucose infusion for at least 
24  h or conventional therapy. After discharge, the 
patients were managed by their physician, with a rec-
ommendation to maintain HbA1c < 7%. The groups 
had similar in-hospital mortality rates.
15. In patients undergoing cardiac surgery, it is 
recommended that blood glucose be maintained in the 
120–150 mg/dL range through continuous intravenous 
insulin infusion during the hospitalization period. [I, A]
Summary of evidence
  • Hyperglycemia before or after cardiac surgery has 
been associated with increased risk of complications 
(death, prolonged mechanical ventilation, renal fail-
ure, stroke, and deep sternal infection) [68, 69].
  • The observational Portland Diabetes Project study 
evaluated the relationship between hyperglycemia 
and adverse outcomes of cardiac surgery in patients 
with diabetes. In the study, continuous intravenous 
insulin, adjusted by frequent blood glucose tests was 
used based on a standardized protocol conducted by 
nurses. Initial glucose target was 150–200  mg/dL. 
This was later changed to 125–175 mg/dL and then 
to 100–150 mg/dL because other studies were identi-
fying the need to normalize blood glucose reduction 
outcomes. The use of this protocol vs. subcutaneous 
insulin according to glucose levels (historical control) 
was associated with reduced rates of infection [70] 
and death in about 50% of patients [71].
  • A randomized controlled trial with surgical inten-
sive coronary unit patients (63% cardiac surgery 
and 13% diabetes) showed benefit of intensive gly-
cemic control (insulin infusion glycemic target 
80–110  mg/dL) vs. usual glycemic control (180–
200 mg/dL) in mortality, infection, acute renal fail-
ure requiring hemodialysis, blood transfusion, and 
polyneuropathy in critically ill patients. However, 
intensive glycemic control was associated with 
higher rates of hypoglycemia [72].
  • Nevertheless, the multicenter NICE SUGAR Study, 
conducted in medical (63%) and surgical intensive 
coronary units (37% of patients respectively; 20% 
with a history of diabetes), showed that intensive gly-
cemic control (target < 108 mg/dL) vs. usual control 
(140–180 mg/dL) increased mortality and hypoglyce-
mia rates [73]. A meta-analysis including data from 
the NICE SUGAR study, with separate analysis of 
clinical and surgical ICUs, showed that tight glucose 
control did not reduce mortality in the clinical ICU, 
but may bring benefit to surgical patients when tar-
get blood glucose is <150 mg/dL [74]. A small RCT 
comparing two glycemic targets (90–120  mg/dL vs. 
120–180  mg/dL) in patients with diabetes undergo-
ing coronary artery bypass grafting showed increased 
risk of hypoglycemia and absence of benefit with 
more strict blood glucose control [75].
16. A basal plus bolus correction insulin regimen (a 
strategy using multiple doses of long‑ and short‑acting 
insulins) is a reasonable option for correcting 
hyperglycemia in hospitalized, non‑critically ill diabetic 
patients. [IIa, B] The use of sliding‑scale insulin in the 
inpatient hospital setting is discouraged. [III, C]
Summary of evidence
  • Hyperglycemia in in-hospital patients with diabetes 
is very common. Retrospective and randomized con-
trolled trials in surgical populations have reported 
that hyperglycemia of diabetes is associated with 
increased length of stay, hospital complications, 
resource utilization, and mortality [76, 77].
  • A randomized controlled trial showed that basal-
bolus treatment (glargine and glulisine) improved 
glycemic control and reduced hospital complications 
(wound infection, pneumonia, acute renal failure, 
and bacteremia) compared with sliding-scale insulin 
(glulisine) in general surgery patients with type 2 dia-
betes [78].
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  • Some RCTs were performed in type 2 diabetic 
patients hospitalized for nonsurgical conditions. In 
this population, basal–bolus treatment (glargine and 
glulisine or NPH and regular) also improved glyce-
mic control compared with sliding-scale insulin [79, 
80].
Outpatient treatment: monotherapy
17. In patients with recently diagnosed type 2 diabetes, 
metformin plus non‑pharmacological therapy 
including physical activity and targeted nutrition therapy 
for weight control is recommended as first‑line therapy. [I, 
A]
Summary of evidence
  • Metformin has a favorable efficacy and safety pro-
file, with important metabolic effects and car-
diovascular benefits. Due to its effect in reducing 
cardiovascular events and mortality, its efficacy 
in blood glucose reduction with low incidence of 
hypoglycemia, low cost, tolerable adverse effects, 
and no association with weight gain, it is the cur-
rent first-line agent of choice for treatment of 
hyperglycemia in type 2 diabetes [81]. Titration or 
addition of further hypoglycemic drugs should be 
implemented as soon as possible to avoid inertia in 
achieving glucose targets.
18. In patients who do not tolerate metformin, any other 
antidiabetic drug can be recommended as monotherapy, 
except if contraindicated. [I, C]
Summary of evidence
  • The UKPDS analyzed 5102 recently diagnosed type 
2 diabetes patients followed up from 1977 to 1997 
and found that intensive glycemic control with sul-
fonylurea or insulin therapy decreases progression of 
microvascular disease and may also reduce the risk of 
heart attacks. In obese patients, the UKPDS showed 
that metformin has similar efficacy to sulfonylureas 
for glucose control [52, 82, 83].
  • UKPDS 34 investigated whether intensive glucose 
control with metformin has any specific advantage 
or disadvantage. A subgroup analysis compared 
411 recently diagnosed overweight (>120% ideal 
bodyweight) type 2 diabetes patients treated with 
diet alone versus 342 patients using metformin, 
aiming for a fasting plasma glucose <110  mg/dL, 
and found a relative risk reduction (RRR) of 32% 
(p  =  0.002) of any diabetes-related complica-
tions, a 42% RRR for any death related to diabetes 
(p = 0.017), and a 36% RRR for all-cause mortality 
(p = 0.011).
19. In patients with renal impairment, possible 
substitutions of anti‑hyperglycemic drugs for type 2 
diabetes are indicated in Table 6
Outpatient treatment: second agent 
20. In an asymptomatic patient with recently diagnosed 
type 2 diabetes and HbA1c > 8.5%, combined 
pharmacological treatment for hyperglycemia consisting 
of metformin plus a second antihyperglycemic agent 
should be considered as first‑line therapy. [IIa, C]
Summary of evidence
  • This is an expert opinion-based recommendation, 
not based on published evidence. The majority of 
members from the Panel recommends to start com-
bined therapy with metformin above HbA1c > 8.5% 
to avoid delaying the attainment of optimal glycemic 
control; all efforts should be made to prevent severe 
hyperglycemia in treatment-näive patients with type 
2 diabetes.
Table 6 Renal function adjustments of anti-hyperglycemic 
drugs
GFR glomerular filtration rate, NN not necessary, NR not recommended, bid 2 
times daily
Drug Maximal 
daily dose
Estimated GFR (mL/min)
45–60 30–45 <30
Insulin Variable NN NN NN
Pioglitazone 45 mg NN NN NN
Linagliptin 5 mg NN NN NN
Sitagliptin 
(mg)
100 50 50 25
Vildagliptin 50 mg bid 50 mg 50 mg 50 mg
Saxagliptin 
(mg)
5 2.5 2.5 2.5
Alogliptin 
(mg)
25 12.5 12.5 6.25
Metformin <2550 mg <2000 mg/
day
<1000 mg/
day
NR
Glimepiride 8 mg 1 mg 1 mg NR
Gliclazide 120 mg NN NN NR
Glibenclamide 20 mg NR NR NR
Nateglinide 120 mg/meal 60 mg/meal 60 mg/meal NR
Repaglinide 
(mg/meal)
1 0.5 0.5 0.5
Acarbose 300 mg 150 mg 150 mg NR
Exenatide 10 mcg bid NN 5 mcg bid NR
Liraglutide 1.8 mg NN NN NR
Lixisenatide 20 mcg NN NR NR
Dulaglutide 1.5 mg/week NN NN NR
Canagliflozin 300 mg 100 mg NR NR
Empagliflozin 25 mg NN NN NR
Dapagliflozin 10 mg NN NR NR
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21. In patients who do not achieve target HbA1c 
levels on monotherapy, any antidiabetic drug is 
potentially effective as an add‑on option to metformin 
for glycemic control. There is no evidence of significant 
differences between classes of antidiabetic agents 
when used as second therapy added to metformin. [I, A] 
Pharmacological therapy to lower blood glucose in the 
patient with type 2 diabetes should be individualized 
on the basis of efficacy, mechanism of action, presence 
of comorbidities, risk of hypoglycemia, weight gain, 
adverse effects, and costs. [I, C]
Summary of evidence
  • A meta-analysis [84] including 27 RCTs with 11,198 
type 2 diabetes patients showed a similar HbA1c 
reduction between different classes of antidiabetic 
agents compared to placebo. The mixed-treatment 
comparison showed the following reductions in 
HbA1c: sulfonylureas, 0.79%; glinides, 0.65%; thia-
zolidinediones, 0.85%; α-glucosidase inhibitors, 
0.64%; DPP-4 inhibitors, 0.78%; and GLP-1 ana-
logues, 0.97%. Thiazolidinediones, sulfonylureas, 
and glinides were associated with mild weight gain, 
while GLP-1 analogues were associated with a sig-
nificant decrease in body weight compared with 
placebo (−1.74  kg). There was no weight change 
associated with α-glucosidase inhibitors or DPP-4 
inhibitors. Sulfonylureas and glinides were associated 
with an increased risk of hypoglycemia compared 
with placebo [84]. The choice of second antidiabetic 
agent should be based on efficacy, age, mechanism 
of action, risk of hypoglycemia, presence of comor-
bidities, life expectancy, weight gain or loss, adverse 
effects, and potential for cardiovascular protection 
[85].
Outpatient treatment: third agent
22. There is also no difference in HbA1c reduction 
when different classes of drugs are used as a third 
option for the treatment of type 2 diabetes. This panel 
recommends that any antidiabetic drug could be an option 
as a third agent for glycemic control, provided that the 
mechanism of action is not similar to that of agents already 
in use. [I, C]
Summary of evidence
  • A meta-analysis of 18 RCTs (n-4535) evaluated the 
comparative efficacy of GLP-1 agonists, DPP-4 inhib-
itors, thiazolidinediones, and α-glucosidase inhibitors 
in reducing HbA1c, body weight, and causing severe 
hypoglycemia when a third drug was added to a met-
formin plus sulfonylurea regimen [86]. Despite limi-
tations, as most of the studies were of short duration, 
with variable quality, and based on indirect compari-
sons, the meta-analysis showed that all antidiabetic 
classes were associated with significant reductions 
in HbA1c levels compared to placebo. The overall 
average reduction in Hba1c was −0.96% (thiazoli-
dinediones, −1.15%; acarbose, −0.6%; GLP-1 ago-
nists, −1.04%; DPP-4 inhibitors, −0.89%). There was 
no clear difference in efficacy between drug classes 
when adding a third agent to treatment of patients 
with type 2 diabetes who were already receiving met-
formin and a sulfonylurea [86].
23. Insulin therapy (with or without additional agents) 
should be considered any time in patients with type 2 
diabetes who present persistently high blood glucose 
levels despite antidiabetic agent combinations, or 
in patients who are markedly symptomatic. [I, C]
Summary of evidence
  • After at least 3 months using metformin plus a sec-
ond antidiabetic agent, if the glycemic target is not 
reached, a third drug should be chosen, taking into 
account the established therapeutic target, age, 
patient limitations, and the attributes and side effects 
of each drug. Consider initiating insulin therapy 
(with or without additional agents) in patients with 
type 2 diabetes who remain markedly symptomatic 
(weight loss, ketosis, polyuria, or polydipsia) and/or 
exhibit elevated blood glucose levels or HbA1c [85].
24. Insulin is a safe option for glycemic control in type 2 
diabetic patients treated with one or more antidiabetic 
agents who do not achieve HbA1c targets or who have 
typical symptoms of hyperglycemia, even in the presence 
of high cardiovascular risk. [I, A]
Summary of evidence
  • The UKPDS [52] and ORIGIN [87] are randomized 
controlled trials that used human insulin and the 
insulin analogue glargine, respectively, in type 2 dia-
betes and evaluated long-term cardiovascular out-
comes. The UKPDS revealed a 15% reduction in 
myocardial infarction and a 13% reduction in death 
among people with new-onset type 2 diabetes treated 
intensively with antidiabetic agents and insulin, as 
needed to attain an HbA1c of 7.0% vs. usual care. The 
mean follow up was of 10 years [52].
  • In the ORIGIN study [87], participants were randomly 
assigned to insulin glargine added as an evening injec-
tion to their preexisting anti-hyperglycemic regimen or 
to standard care (treatment according to the investiga-
tor’s discretion in alignment with local guidelines). The 
study included 12,537 people, 88% of whom with type 
2 diabetes, of which 59% had a previous cardiovascular 
event. After a mean follow up of 6.2  years, no differ-
ences were found between groups concerning the com-
posite endpoint of nonfatal myocardial infarction, non-
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fatal stroke or cardiovascular death. These data indicate 
that basal insulin treatment (human insulin or insulin 
analogues) is safe in individuals with type 2 diabetes 
with or without pre-existing cardiovascular events.
  • In the DEVOTE study (Efficacy and Safety of deglu-
dec versus glargine in type 2 diabetes), 7637 patients 
with type 2 DM were randomized to receive either 
insulin degludec or insulin glargine U100. The pri-
mary outcome (nonfatal myocardial infarction, non-
fatal stroke and cardiovascular death) occurred in 
8.5% of the patients treated with degludec and in 
9.3% of the patients treated with glargine (hazard 
ratio  =  0.91; p  =  non-significant). Patients treated 
with degludec experienced significant lower rates of 
severe hypoglycemia in comparison to the glargine 
U100 group (p < 0.001) [88].
Cardiovascular risk
25. In type 2 diabetic patients at VERY HIGH RISK 
(presence of clinical atherosclerotic disease, with previous 
cardiovascular events), the addition of an SGLT‑2 inhibitor 
with demonstrated cardiovascular benefit can be useful 
to reduce cardiovascular risk, as it reduces the incidence 
of cardiovascular events and hospitalization due to heart 
failure in this population. [IIa, A]
Summary of evidence
  • The EMPA-REG study of empagliflozin, an inhibitor 
of sodium glucose co-transporter-2 (SGLT2), evalu-
ated 7020 high-risk patients with type 2 diabetes. 
After 3.1 years, empagliflozin therapy was associated 
with a 14% reduction in the composite primary out-
come of CV mortality, nonfatal AMI, and nonfatal 
stroke (10.5% vs. 12.1%, p =  0.04; NNT 62), as well 
as a reduction in all-cause mortality (5.7% vs. 8.3%, 
p  <  0.001; RRR −32%, NNT 38). There was also a 
reduction in cardiovascular mortality (3.7% vs. 5.9%, 
p  <  0.001; RRR −38%, NNT 45) [89]. Interestingly, 
the HbA1c reduction with empagliflozin was modest 
(0.5%). The mechanisms by which the drug may have 
led to this significant result are still being studied.
  • The CANVAS Program (Canagliflozin and Cardiovas-
cular and Renal Events in Type 2 Diabetes) included 
10,142 patients with type 2 DM, including individu-
als with established cardiovascular disease (second-
ary prevention) and patients at high risk for CV events 
(primary prevention). Patients were then randomized 
for Canagliflozin (100 mg and 300 mg) or placebo, and 
were followed for a mean of 188.2  weeks. Canagliflo-
zin therapy was associated with a 14% reduction in the 
composite primary outcome of CV mortality, nonfatal 
AMI, and nonfatal stroke (occurring in 26.9 vs. 31.5 
participants per 1000 patients-years). However, patients 
receiving canagliflozin experienced a significant 
increase in rates of amputation (6.3% vs. 3.4%; p < 0.001) 
and bone fractures (15.4% vs. 11.9%; p = 0.02) [90].
  • Both EMPA-REG and CANVAS demonstrated a sig-
nificant reduction in a secondary endpoint composed 
of hospitalization for heart failure and cardiovascular 
death.
26. In type 2 diabetic patients with clinical atherosclerotic 
disease (CLAD) (i.e., VERY HIGH‑RISK patients), the addition 
of a GLP‑1 analogue with demonstrated cardiovascular 
benefit may be useful to reduce cardiovascular risk, as it 
seems to decrease the incidence of cardiovascular events 
in this population. [IIa, A]
Summary of evidence
  • The LEADER study of liraglutide, a GLP-1 analogue, 
assessed 9340 type 2 diabetes patients with high car-
diovascular risk profile. After 3.8 years of follow-up, 
liraglutide was associated with a 13% reduction in 
the composite primary outcome of CV mortality, 
nonfatal AMI, and nonfatal stroke (13% vs. 14.9%, 
p  =  0.01). There were reductions in cardiovascular 
mortality (4.7% vs. 6%, p  =  0.007; RRR −22%) and 
all-cause mortality (8.2% vs. 9.6%; p  =  0.02; RRR 
−15%). There was no reduction in the incidence of 
nonfatal AMI, nonfatal stroke, or hospitalization for 
heart failure [91].
  • The SUSTAIN-6 trial analyzed 3297 patients with 
longstanding type 2 diabetes (mean disease dura-
tion 13.9  years) and established cardiovascular dis-
ease, chronic kidney disease, or both, on a standard 
care regimen, who were randomly assigned to receive 
once-weekly semaglutide (0.5 or 1.0  mg) or placebo 
for 104 weeks. At 2-year follow-up, there was a 26% 
reduction in the composite primary outcome or CV 
mortality, nonfatal AMI, and nonfatal stroke (6.6% vs. 
8.9%, p = 0.02) [92]. Cardiovascular death was simi-
lar in the two groups (p = 0.92). Nonfatal stroke was 
the main composite primary outcome driver (1.6% 
vs. 2.7%, p =  0.04; RRR –39%). Diabetic retinopathy 
was more frequent in the semaglutide group (3%) 
than the placebo group (1.8%) (HR 1.76, 95% CI 1.11–
2.78, p = 0.02). How much of this is due to a greater 
decrease in HbA1c still needs to be clarified (1% dif-
ference between semaglutide 1 mg and placebo).
27. In type 2 diabetic patients, at any level of risk 
of cardiovascular events, pioglitazone, DPP4 inhibitors, 
or GLP‑1 analogues are safe and reasonable options 
to achieve glycemic control. [I, A]
Summary of evidence
  • The use of pioglitazone in patients with long term 
type 2 diabetes and preexisting CV disease margin-
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ally reduced fatal and nonfatal myocardial infarc-
tion when compared to placebo (RRR −16%, 95% 
CI 0.72–0.98, p  <  0.03). However, there was a two-
fold risk of hospitalization for heart failure and an 
increased risk of bone fractures in women, but no 
increase in mortality risk [93].
  • Recently, several DPP-4 inhibitors and GLP-1 ana-
logues have been evaluated for global CV safety and 
mortality outcomes in patients with type 2 diabetes 
at high risk of CV events.
  • The TECOS (sitagliptin) study enrolled 14,671 
patients with longstanding type 2 diabetes (mean dis-
ease duration 11.6 years), preexisting CV disease, and 
a mean baseline HbA1c of 7.2% [94].
  • The SAVOR-TIMI 53 (saxagliptin) study examined 
16,492 patients with longstanding type 2 diabetes 
(mean disease duration 10.3  years), preexisting CV 
disease or multiple risk factors, and an average base-
line HbA1c of 8% [95].
  • The EXAMINE (alogliptin) study evaluated 5380 
patients with type 2 diabetes (mean disease duration 
7.2  years) associated with acute coronary syndrome 
and average baseline HbA1c of 8% [96].
  • The ELIXA (lixisenatide) study examined 6068 
patients with type 2 diabetes (mean disease duration 
9.4 years) associated with preexisting coronary artery 
disease with a recent hospital admission due to acute 
coronary syndrome and mean baseline HbA1c of 
7.6% [97].
  • Importantly, these studies were designed for noninfe-
riority and demonstrated neutrality regarding global 
CV safety in patients with type 2 diabetes at high 
risk of CV events. Saxagliptin was associated with an 
unexpected increase in hospitalization for heart fail-
ure [94–97].
28. In type 2 diabetic patients at any level of cardiovascular 
risk, the use of sulfonylureas is safe and a reasonable 
option to achieve glycemic control. However, careful 
use of sulfonylureas is advocated because of a possible 
increased risk of hypoglycemia (especially in the elderly), 
as well as weight gain. [IIa, B]
Summary of evidence
  • A meta-analysis of 47 RCTs (n = 37,650) evaluated 
the safety of the most frequently used sulfonylureas, 
in an attempt to elucidate conflicting data regard-
ing the safety of this class of antidiabetics in terms 
of mortality and cardiovascular outcomes. The 
result showed that sulfonylureas were not associ-
ated with all-cause mortality (RR 12%, 95% CI 0.96–
1.30) or cardiovascular mortality (RR 12%, 95% CI 
0.87–1.42). Sulfonylureas were not associated with 
increased risk of myocardial infarction (RRR −8%, 
95% CI 0.76–1.12) or stroke (RR 16%, 95% CI 0.81–
1.66) [98].
  • The Action in Diabetes and Vascular Disease: Pre-
terax and Diamicron Modified Release Controlled 
Evaluation (ADVANCE) study and the ADVANCE-
ON post-trial study were the largest (and with the 
highest CV risk population) ever conducted in 
patients with diabetes on sulfonylurea therapy in 
which cardiovascular outcomes were determined. 
The ADVANCE trial randomly assigned 11,140 
patients with type 2 diabetes, of whom 32% had pre-
existing cardiovascular disease, to undergo either 
standard glucose control or intensive glucose con-
trol, defined as the use of gliclazide MR 60  mg/
day to 120  mg/day, plus other drugs, to achieve 
an HbA1c value of 6.5% or less. After a median of 
5  years of follow-up, the mean HbA1c level was 
lower in the intensive-control group (6.5%) than 
in the standard-control group (7.3%). Intensive 
control reduced the incidence of combined major 
macrovascular and microvascular events (18.1%, 
vs. 20.0% with standard control; HR 0.90, 95% CI 
0.82–0.98, p  =  0.01). This was due primarily to a 
reduction in the incidence of nephropathy (4.1% 
vs. 5.2%; HR 0.79, 95% CI 0.66–0.93, p  =  0.006). 
Importantly, there was no increase in death from 
all causes (p = 0.91) nor from cardiovascular causes 
(p = 0.63). The ADVANCE-ON study invited 8944 
surviving participants from the ADVANCE study 
to a 6-year post-trial study, defining death from any 
cause and major macrovascular events as primary 
endpoints. Between-group differences in HbA1c 
levels during the trial were no longer evident. No 
differences were observed in risk of death from any 
cause (p=) or major macrovascular events between 
the intensive-control group and the standard-con-
trol group (HR 1.00, 95% CI 0.92–1.08 and HR 1.00, 
95% CI 0.92–1.08 respectively).
Module 5: Management of dyslipidemia
29. In patients with diabetes at VERY HIGH RISK, the 
recommended lipid target is to reduce LDL‑c to a level 
below 50 mg/dL or non‑HDL‑c to a level below 80 mg/
dL (Table 7). For patients not on statin treatment, at 
any baseline LDL‑c level, an initial reduction in LDL‑c 
or in non‑HDL‑c of more than 50% from baseline is 
recommended. [I, A]
30. If, in VERY HIGH‑risk patients, after 3 months, targets 
are not met, treatment must be intensified. [I, C]
Summary of evidence
  • Two double-blind, controlled, randomized clinical 
trials have demonstrated that reducing the levels of 
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LDL-c cholesterol to below (or near) 50  mg/dL is 
associated with a significant reduction in the inci-
dence of major cardiovascular events. In the FOU-
RIER trial [99], 27,564 patients with atherosclerotic 
cardiovascular disease and under statin therapy were 
randomized to placebo or evolocumab. Patients 
randomized to evolocumab had their LDL-c levels 
reduced to 30  mg/dL and had a significant reduc-
tion in major cardiovascular events (9.8% in the 
evolocumab group vs 11.3% in the placebo group, 
hazard ratio 0.85, p  <  0.001). In the IMPROVE-IT 
trial [100], 18,144 patients who had been hospital-
ized for acute coronary syndrome in the preceding 
10  days were randomized to simvastatin or simvas-
tatin + ezetimibe. Patients randomized to simvasta-
tin plus ezetimibe had their LDL-c levels reduced to 
53.7  mg/dL and experienced a significant reduction 
in cardiovascular events (32.7% for the simvastatin/
ezetimibe group vs 34.7% for the simvastatin group, 
hazard ratio 0.936, p = 0.016).
  • Statins have largely been proven to reduce the risk of car-
diovascular events in patients with diabetes with a pre-
vious history of vascular events. A meta-analysis of 14 
trials including 18,686 patients with diabetes concluded 
that statin treatment reduces the incidence of vascu-
lar events proportionately by 20% for each 39  mg/dL 
reduction in LDL-c in 5 years, with a similar reduction 
for major coronary events, stroke, and need for revas-
cularization [101].
  • In a meta-analysis of individual data from 8 statin 
RCTs [102] including 38,153 patients allocated into 
statin therapy, in which lipids and apolipoproteins 
were determined at baseline and after 1  year of fol-
low-up, a total of 6286 major cardiovascular events 
were observed in 5387 study participants. Patients 
with LDL-c below 50  mg/dL were at significantly 
lower risk than patients with increased levels of LDL-
c. The risk category was proportionally lower as the 
level of LDL-c decreased. Compared with patients 
whose LDL-c was >175 mg/dL, those who reached an 
LDL-c of 75–100 mg/dL, 50–75 mg/dL, and <50 mg/
dL respectively had progressively lower adjusted HRs 
of 0.56 (95% CI 0.46–0.67), 0.51 (95% CI 0.42–0.62), 
and 0.44 (95% CI 0.35–0.55) for major cardiovascular 
events. Similar associations were observed for non-
HDL-c and apolipoprotein B. LDL-c limits may be 
transferred to non-HDL-c limits by adding 30 mg/dL 
[103].
  • Non-HDL-c is calculated by subtracting HDL-c from 
total cholesterol. This measure is not affected by tri-
glyceride concentration and is better than calculated 
LDL-c in patients with increased plasma triglyceride 
concentrations.
31. Patients with diabetes in the VERY HIGH‑RISK 
category should initiate statins as soon as possible at the 
highest tolerable dose (Table 8) to meet cholesterol 
targets (Table 7). The lipid profile should be reviewed 
every 1–3 months. If targets are not met, intensification 
of treatment is advised, either by switching to a more 
potent statin, increasing statin dose, adding ezetimibe, 
and/or improving lifestyle modifications. [I, A]
Summary of evidence
  • A pre-specified subgroup analysis of the treat to 
new targets (TNT) study [104], which included 
1501 patients with diabetes and coronary artery dis-
ease, compared the impact of atorvastatin 80 mg vs. 
10 mg on cardiovascular outcomes during 4.9 years. 
The study showed a significant reduction in any car-
diovascular event and stroke in the 80 mg arm. The 
lower LDL-c attained with the highest dose showed 
additional benefit.
Table 7 Cholesterol targets 
in patients with diabetes
Level of risk Off statin treatment On statin treatment
% Reduction LDL-c (mg/dL) Non-HDL-c (mg/dL)
LOW 30–50 <100 <130
INTERMEDIATE 30–50 <100 <130
HIGH >50 <70 <100
VERY HIGH >50 <50 <80
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  • A meta-analysis of five randomized trials [105] 
(39,612 subjects with prior vascular disease, 5639 
[14%] with diabetes) compared intensive vs. mod-
erate statin treatments. Mean follow-up was of 
5.1  years. Intensive treatment was defined as a 
reduction in LDL-c of 20  mg/dL beyond the result 
obtained by moderate treatment with the use of 
higher-potency statins. The results showed a 15% 
further reduction in major vascular events (95% CI 
11–18, p  <  0.0001), 13% in coronary death (95% CI 
7–19, p  <  0.0001), 19% in coronary revasculariza-
tion (95% CI 15–24), p < 0.0001) and 16% in stroke 
(95% CI 0.74–0.95, p =  0.005). Moderate treatment 
promoted a 30% decrease in cardiovascular events 
compared to placebo. Intensive treatment promoted 
a 20% reduction in cardiovascular events beyond 
moderate treatment. Thus, the overall reduction in 
events with intensive treatment compared to moder-
ate treatment was 50%.
  • Treatment goals, even with the highest tolerated sta-
tin dose, may not be reached by patients with dyslipi-
demia, particularly those with established CVD, DM, 
or asymptomatic high-risk individuals. In such cases, 
combination treatment may be needed. However, the 
only combination with evidence of clinical benefit 
(one large RCT) is that of a statin and with ezetimibe 
[100]. Based on the relatively limited evidence, the 
ESC/EAS 2016 panel recommends restricted use of 
this combination in patients at high or very high risk 
of CVD [103].
32. The use of PCSK9 inhibitors may be considered in VERY 
HIGH‑RISK patients who do not meet LDL‑c targets 
despite high intensity statin use. The decision to use 
PCSK9 inhibitors, however, must be carefully evaluated 
through cost‑benefit analysis. [IIa, B]
  • Monoclonal antibody inhibitors of proprotein con-
vertase subtilisin–kexin type 9 serine protease 
(PCSK9), a protein that regulates the recycling of 
LDL receptors, have recently been approved by the 
FDA, EMEA, and ANVISA for primary prevention 
in patients with hetero- and homozygous famil-
ial hypercholesterolemia or as secondary preven-
tion in patients with CLAD who require additional 
LDL-c–lowering therapy. This class of drugs meets 
a large unmet need for more aggressive lipid-lower-
ing therapy beyond statins in an attempt to further 
reduce residual risk in many persons with clinical 
CLAD and diabetes. When added to maximal sta-
tin therapy, these once- or twice-monthly injectable 
agents reduce LDL-c by approximately 60%, and have 
favorable effects on other lipids [106–112]. In post 
hoc cardiovascular safety analyses of alirocumab 
and evolocumab added to statins with or without 
other lipid-lowering therapies, mean LDL-c levels 
of 48  mg/dL were associated with statistically sig-
nificant relative risk reductions of 48–53% in major 
CLAD events [107, 108]. Furthermore, a subgroup 
analysis of patients with diabetes taking alirocumab 
demonstrated that a 59% LDL-c reduction was asso-
ciated with a CLAD event relative risk reduction 
trend of 42% [113].
  • The FOURIER study [99] was a randomized, dou-
ble-blind, placebo controlled trial which evaluated 
whether the PCSK9 inhibitor evolocumab associated 
with a statin could reduce cardiovascular risk vs. sta-
tin therapy alone in patients with clinically evident 
atherosclerotic cardiovascular disease and LDL-c lev-
els of 70 mg/dL. After 48 weeks, evolocumab reduced 
LDL-c from a baseline of baseline of 92–30  mg/dL 
and met its primary composite endpoint, reducing 
cardiovascular death, nonfatal myocardial infarc-
tion (MI), nonfatal stroke, hospitalization for unsta-
ble angina or coronary revascularization in 15% 
(p  <  0.001). The key secondary composite endpoint 
(cardiovascular death, nonfatal MI or nonfatal stroke) 
was also reduced in 20% (p < 0.001). No new safety 
issues were observed.
  • In the GLAGOV study [114], in patients with 
angiographic coronary disease treated with statins, 
addition of evolocumab, compared with placebo, 
resulted in a greater decrease in PAV (percent ath-
eroma volume) after 76  weeks of treatment. The 
evolocumab group achieved lower mean, time-
weighted LDL-c levels (93.0 vs. 36.6  mg/dL; dif-
ference, −56.5  mg/dL [95% CI −59.7 to −53.4], 
p  <  0.001). The primary efficacy parameter, PAV, 
increased 0.05% with placebo and decreased 0.95% 
with evolocumab (difference, −1.0% [95% CI −1.8 
to −0.64%], p  <  0.001). The secondary efficacy 
Table 8 Mean expected % of  LDL-c reduction with  statin 
use
Statin Mean expected LDL‑c reduction (%)
<30 (mg) 30–50 (mg) ≥50
Simvastatin 10 20–40 40 mg + ezetimibe
Pravastatin 10–20 40–80 –
Fluvastatin 20–40 80 –
Atorvastatin – 10–20 40–80 mg
Rosuvastatin – 5–10 20–40 mg
Pitavastatin 1 2–4 –
Lovastatin 20 40 –
Page 17 of 36Bertoluci et al. Diabetol Metab Syndr  (2017) 9:53 
parameter, normalized TAV (total atheroma vol-
ume), decreased 0.9 mm3 with placebo and 5.8 mm3 
with evolocumab (difference, −4.9  mm3 [95% CI 
−7.3 to −2.5]; p  <  0.001). Evolocumab induced 
plaque regression in a greater percentage of patients 
than placebo (64.3% vs. 47.3%; difference, 17.0% 
[95% CI 10.4–23.6], p  <  0.001 for PAV and 61.5% 
vs. 48.9%; difference, 12.5% [95% CI 5.9–19.2%], 
p < 0.001 for TAV) [114].
33. In patients with diabetes at VERY HIGH RISK 
(Tables 2, 5) with a recent acute coronary syndrome, 
lipid profile should be determined in the first 12–24 h 
of hospitalization to define baseline levels. Subsequently, 
statin treatment should be started at the highest tolerable 
doses, as soon as possible, for 3 months, independently 
of lipid levels. At that time, lipid profile should be 
reassessed to check for target achievement. [I, B]
Summary of evidence
  • The double-blind, randomized IMPROVE IT trial 
[100] studied 18,144 patients who had been hospi-
talized for acute coronary syndrome within the pre-
ceding 10 days and had LDL-c levels of 50–100 mg/
dL while on lipid-lowering therapy or 50–125  mg/
dL if they were not receiving lipid-lowering ther-
apy. The combination of simvastatin (40  mg) and 
ezetimibe (10  mg) (simvastatin–ezetimibe) was 
compared with simvastatin (40  mg) and placebo. 
The primary outcome was the composite of car-
diovascular death, nonfatal myocardial infarction 
and unstable angina requiring re-hospitalization, 
coronary revascularization, or nonfatal stroke. The 
median follow-up was 6  years. The median time-
weighted mean LDL-c level during the study was 
53.7  mg/dL in the simvastatin–ezetimibe group, 
as compared with 69.5  mg/dL in the simvastatin 
alone group (p < 0.001). The event rate for the pri-
mary endpoint at 7 years was 32.7% in the simvas-
tatin–ezetimibe group, as compared with 34.7% in 
the simvastatin-alone group, with an absolute risk 
difference of 2.0% (HR 0.936, 95% CI 0.89–0.99, 
p  =  0.016). Thus, vigorous reduction of LDL-c 
in the early phases of acute coronary syndrome 
resulted in improved cardiovascular outcomes and 
should be recommended. In addition, subgroup 
analysis revealed the greatest benefit in patients 
with diabetes, with a 15% reduction in the primary 
endpoint and a NNT = 18 [100].
34. In patients with diabetes at HIGH RISK 
(Tables  2, 3, 4), LDL-c should be maintained below 
70 mg/dL and/or non-HDL-c below 100 mg/dL. [I, A]
35. Alternatively, in HIGH‑RISK diabetic patients not 
using statins, an initial reduction of >50% in LDL‑c or 
in non‑HDL‑c is recommended. If, after 3 months, targets 
are not met (LDL‑c < 70 mg/dL or non‑HDL‑c < 100 mg/dL), 
treatment should be intensified. [I, C]
Summary of evidence
  • The Collaborative Atorvastatin Diabetes Study 
(CARDS) [115], which was terminated early for effi-
cacy, assessed 2838 patients with diabetes without 
coronary artery disease (age 40–75 years) and at least 
1 additional risk factor (microalbuminuria, retinopa-
thy, hypertension, or smoking). Patients were ran-
domized to atorvastatin 10  mg or placebo during a 
mean follow-up of 3.9  years, a composite of acute 
coronary events, coronary revascularization, or 
stroke as primary outcome. Atorvastatin 10 mg was 
associated with risk reduction of 37% (95% CI −52 to 
−17, p = 0.001) in the primary endpoint, reduction 
of 32% (95% CI −45 to −15, p = 0.001) in stroke risk, 
and a trend toward 27% reduction in total mortality 
(95% CI −48 to 1.0, p  =  0.059). The CARDS esti-
mated that one event is avoided for every 27 patients 
treated for 4 years.
  • In the MRC/BHF Heart Protection Study (HPS) 
substudy [116], 5963 individuals with diabetes (age 
40–80 years) were randomized to simvastatin 40 mg 
or placebo. A pre-specified subgroup analysis was 
performed for the outcomes of fatal and nonfatal 
acute myocardial infarction (AMI) and first vascular 
event (major coronary event, stroke, or revasculari-
zation). Simvastatin 40  mg reduced these outcomes 
by 33% (95% CI 17–46, p  <  0.0003), regardless of 
baseline LDL-c level. The absolute reduction of cardi-
ovascular disease risk in patients with diabetes with-
out coronary artery disease was similar for the HPS 
and the CARDS studies. This confirms the benefit of 
statins for primary prevention in high-risk patients 
with diabetes.
  • In the pre-specified subgroup analysis of the treat to 
new targets (TNT) study [104], with 1501 patients 
with diabetes and coronary artery disease, inten-
sive treatment with atorvastatin 80  mg was associ-
ated with a significant reduction in any cardiovas-
cular events and stroke compared with atorvastatin 
10 mg in a 4.9-year follow-up. Patients taking 10 mg 
achieved an average level of LDL-c of 96  mg/dL, 
while those using 80  mg/day achieved 77  mg/dL. 
Thus, the attainment of a target LDL-c below 70 mg/
dL showed additional benefit.
  • A systematic search and meta-analysis including 11 
trials was performed to evaluate the impact of statin 
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therapy on carotid intima media thickening (CIMT) 
progression. Statin therapy was found to slow the 
progression of carotid atherosclerosis, indicating 
benefits at the subclinical stage of the disease process 
[117].
36. In patients with diabetes at HIGH RISK, with either 
stratifying factors (Table 3) or confirmed subclinical 
atherosclerosis (Table 4), it is highly recommended to start 
statin therapy (Table 8) to meet targets (Table 7). [I, A]
37. If, after 3 months, LDL‑c or non‑HDL‑c is not at the 
defined target, intensification of therapy should be 
considered. [IIa, B]
Summary of evidence
  • In the CTT meta-analysis [105] moderate treatment 
promoted a 30% decrease in cardiovascular events 
compared to placebo. Intensive treatment promoted 
a 20% reduction in cardiovascular events beyond 
moderate treatment. Thus, there was an overall 50% 
reduction in events with intensive treatment com-
pared to moderate treatment. Despite the indirect 
evidence provided by subgroup analysis of diabetic 
patients in the meta-analysis, the absence of het-
erogeneity makes these results applicable to patients 
with DM in primary prevention.
38. In patients with diabetes at LOW‑INTERMEDIATE 
RISK, LDL‑c levels should be lowered and maintained 
below 100 mg/dL and non‑HDL‑c levels should be lowered 
and maintained below 130 mg/dL (Table 7). [I, B]
Summary of evidence
  • In a meta-analysis of 14 trials including 18,686 indi-
viduals with diabetes, statin therapy reduced all-
cause mortality and vascular mortality, and the 
reduction in vascular events was proportional to the 
LDL-c reduction. The proportional effects of statins 
in diabetic patients were similar irrespective of prior 
history of vascular disease or other baseline clinical 
conditions [101].
39. Statins are initially optional for LOW RISK patients, 
but should be considered in INTERMEDIATE RISK 
patients (Table 9), if LDL‑c and non‑HDL‑c are above the 
targets (Table 7). Lipid profile should be re‑checked 
periodically to ensure that LDL‑c level is below 100 mg/
dL. Intensification of treatment is needed if targets are not 
met. [IIa, C]
Summary of evidence
  • The TRIALIST meta-analysis [118] compared the 
effects of lowering cholesterol with statins on the 
incidence of cardiovascular events in a low-risk pop-
ulation. The meta-analysis included 22 statin vs. con-
trol trials (n =  134,537) with mean follow-up dura-
tion of 4.8  years, and five more vs. less statin trials 
(n = 39,612) with 5.1 years of follow-up. Participants 
were separated into five categories of baseline 5-year 
major vascular event risk on control therapy (<5, ≥5 
to <10, ≥10 to <20, ≥20 to <30, ≥30%), with estima-
tion of the rate ratio (RR) per 1.0-mmol/L LDL-c 
reduction in each category. Reduction of LDL choles-
terol with a statin reduced the risk of major vascular 
events (RR 0.79, 95% CI 0.77–0.81, per 1.0  mmol/L 
reduction), irrespective of age, sex, baseline LDL-c, 
or previous vascular disease, and of vascular and all-
cause mortality. The proportional reduction in major 
vascular events was at least as great in the two lowest 
risk categories as in the higher risk categories. This 
reflected significant reductions in major coronary 
events in the two lowest risk categories. In individu-
als with 5-year risk of major vascular events <10%, 
each 1-mmol/L reduction in LDL-c produced an 
absolute reduction in major vascular events of about 
11 per 1000 over 5  years. These data indicate that 
low-risk populations also benefit from lowering cho-
lesterol with statins. 
40. It is recommended that patients with diabetes 
and LDL‑c > 190 mg/dL be investigated for familiar 
hypercholesterolemia (FH). [I, C]
Summary of evidence
  • The diagnosis of FH in patients with diabetes should 
be always considered and further investigated 
when an LDL-c level  >  190  mg/dL is found [106]. 
LDL-c  >  250  mg/dL in a patient aged 30 or older, 
LDL-c  >  220  mg/dL in patients aged 20–29, and 
LDL-c  >  190  mg/dL in patients under age 20 yields 
approximately 80% probability of FH in the setting of 
general population screening [107].
41. It is recommended that patients with diabetes 
and chronic kidney failure who are on dialysis, 
without CLAD (Table 5), do NOT initiate use of statins, 
since there is no evidence of benefit in this population 
and, in fact, the risk of stroke may increase. [III, A] However, 
in patients with chronic renal failure who were already 
on statin therapy before initiation of dialysis, withdrawal 
of statins is not recommended. [III, A]
Summary of evidence
  • In the 4D (die deutsche diabetes dialyze) study [119], 
1255 patients with type 2 diabetes on hemodialysis 
were evaluated. They were randomized to atorvas-
tatin 20 mg or placebo and followed up for 4 years. 
The primary endpoint was a composite of death from 
cardiac causes, nonfatal myocardial infarction, and 
stroke. A 42% reduction in LDL-c was observed in 
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patients on atorvastatin, with no reduction in the pri-
mary outcome. The risk of stroke was also increased 
in this group.
  • The study to evaluate the use of rosuvastatin in sub-
jects on regular hemodialysis (AURORA) study 
[120] included 2776 hemodialysis patients (aged 
50–80, 27.9% with diabetes) treated with rosuvastatin 
10 mg/day or placebo during a mean of 3.8 years. The 
primary outcome was a composite of nonfatal myo-
cardial infarction, nonfatal stroke, and cardiovascu-
lar death. There was a 43% reduction in LDL-c in the 
intervention group, but no differences in the primary 
outcome were observed between groups.
  • Regarding patients with chronic renal disease but 
not on hemodialysis, the Pravastatin Pooling Pro-
ject database made a combined analysis of results of 
three randomized trials of pravastatin 40 mg vs. pla-
cebo [121], including 19,700 patients with chronic 
renal insufficiency (estimated GFR 60–30  mL/
min/1.73  m2). Significant benefit of treatment was 
detected in reducing the primary endpoint of myo-
cardial infarction, coronary death, or percutaneous 
revascularization and total mortality in this group of 
patients.
  • The SHARP trial aimed to assess the efficacy and 
safety of the combination of simvastatin plus 
ezetimibe in people with moderate-to-severe kid-
ney disease. This randomized, double-blind trial 
included 9270 patients with chronic kidney disease 
(3023 on dialysis and 6247 not on dialysis) with no 
known history of myocardial infarction or coronary 
revascularization. Patients were randomly assigned 
to simvastatin 20  mg plus ezetimibe 10  mg daily 
versus matching placebo. The key pre-specified out-
come was first major atherosclerotic event (nonfa-
tal myocardial infarction or coronary death, non-
hemorrhagic stroke, or any arterial revascularization 
procedure). All analyses were by intention to treat. A 
total of 4650 patients were assigned to receive simv-
astatin plus ezetimibe, and 4620 to placebo. Alloca-
tion to simvastatin plus ezetimibe yielded an aver-
age LDL cholesterol difference of 33 mg/dL (SE 0.02, 
with about two-thirds of the sample adherent) dur-
ing a median follow-up of 4.9  years, and produced 
a 17% proportional reduction in major atheroscle-
rotic events (526 [11.3%] simvastatin plus ezetimibe 
vs. 619 [13.4%] placebo; rate ratio [RR] 0.83, 95% CI 
0.74–0.94, log-rank p = 0.0021). Patients allocated to 
simvastatin plus ezetimibe did not differ with respect 
to nonfatal myocardial infarction or death from cor-
onary heart disease (213 [4.6%] vs. 230 [5.0%]; RR 
0.92, 95% CI 0.76–1.11, p  =  0.37), and there were 
significant reductions in non-hemorrhagic stroke 
(131 [2.8%] vs. 174 [3.8%]; RR 0.75, 95% CI 0.60–0.94, 
p  =  0.01) and arterial revascularization procedures 
(284 [6.1%] vs. 352 [7.6%]; RR 0.79, 95% CI 0.68–
0.93, p = 0.0036). Adjustment for subgroup-specific 
reductions in LDL-c did not reveal evidence of differ-
ences between the proportional effects on major ath-
erosclerotic events and the summary rate ratio in any 
subgroup examined, and, in particular, in patients 
on dialysis vs. those who were not on dialysis. The 
study concluded that reduction of LDL cholesterol 
with simvastatin 20  mg plus ezetimibe 10  mg daily 
safely reduced the incidence of major atherosclerotic 
events in patients with advanced chronic kidney dis-
ease [122].
  • A sub-analysis of the treating to new targets study 
investigated how intensive lipid lowering with 80 mg 
of atorvastatin affects renal function when compared 
with 10 mg in patients with coronary heart disease. 
A total of 10,001 patients with coronary heart dis-
Table 9 Recommendation for statin treatment according to cardiovascular risk category in diabetes
Risk category Statin treatment
LOW RISK Optionala
INTERMEDIATE RISK Recommended
HIGH RISK Highly recommended
VERY HIGH RISK Mandatory
a Optional means that non-pharmacological (lifestyle) measures are acceptable, provided that an LDL-c target <100 mg/dL is attained and maintained. For patients 
with LDL-c >160 mg/dL, statins are advisable at any risk category
Page 20 of 36Bertoluci et al. Diabetol Metab Syndr  (2017) 9:53 
ease and LDL-c levels  <  130  mg/dL were randomly 
assigned to double-blind therapy with 10 or 80 mg/d 
atorvastatin. Estimated GFR using the modification 
of diet in renal disease equation was compared at 
baseline and at the end of follow-up in 9656 partici-
pants with complete renal data. The expected 5-year 
decline in renal function was not observed. However, 
estimated GFR improved in both treatment groups, 
but was significantly greater with 80  mg than with 
10 mg, suggesting this benefit may be dosage-related 
[123].
  • Another sub-analysis of the TNT study investigated 
the effects of intensive lipid lowering with atorvas-
tatin in patients with coronary heart disease (CHD) 
with and without preexisting chronic kidney disease 
(CKD). The study concluded that aggressive lipid 
lowering with atorvastatin 80 mg was both safe and 
effective in reducing excess cardiovascular events in a 
high-risk population with CKD and CHD [124].
42. In patients with diabetes and class III–IV heart 
failure, initiation of statin therapy is not recommended 
because there is no clear evidence of benefit in this group. 
[III, A]
Summary of evidence
  • The effect of rosuvastatin in patients with chronic 
heart failure (GISSI-HF) randomized, multicenter 
clinical trial evaluated rosuvastatin 10 mg/day com-
pared to placebo in 2285 patients with heart failure 
due to any cause or condition (New York Heart Asso-
ciation classes II–IV); 26% also had diabetes. There 
was no benefit in the outcomes of interest (death and 
hospitalization for cardiovascular causes) [125].
  • The controlled rosuvastatin multinational trial in 
heart failure (CORONA) randomized study com-
pared the use of rosuvastatin 10  mg versus placebo 
in 5011 patients aged >60 years with class II–IV heart 
failure of ischemic etiology (including 29% with dia-
betes). The primary endpoint was a composite of car-
diovascular death, acute nonfatal MI, and nonfatal 
stroke during 36 months. Despite a 45% reduction in 
LDL-c, there was no significant between-group dif-
ference in the primary endpoint. The results were 
extensive to patients with diabetes in the subgroup 
analysis, due to low heterogeneity [126].
  • A retrospective analysis of the CORONA trial com-
pared 10  mg rosuvastatin daily with placebo in 
patients with ischemic systolic heart failure accord-
ing to baseline high sensitivity-C reactive protein 
(hs-CRP) <2.0  mg/L (placebo, n  =  779; rosuvas-
tatin, n =  777) or ≥2.0  mg/L (placebo, n =  1694; 
rosuvastatin, n  =  1711). The primary outcome 
was cardiovascular death, myocardial infarction, 
or stroke. The study demonstrated a significant 
interaction between hs-CRP and the effect of rosu-
vastatin for most endpoints, whereby rosuvastatin 
treatment was associated with better outcomes in 
patients with hs-CRP ≥ 2.0 mg/L [127]. In addition, 
patients with heart failure due to ischemic heart 
disease who had NT-proBNP values <103  pmol/L 
(868 pg/mL) had the best prognosis and, if assigned 
to rosuvastatin rather than placebo, had a greater 
reduction in the primary endpoint (HR 0.65, 95% 
CI 0.47–0.88) than patients in the other tertiles 
(heterogeneity test, p  =  0.0192). This reflected 
fewer atherothrombotic events and sudden deaths 
in the active group, and may show a benefit from 
rosuvastatin use [128].
43. In the patient with diabetes and mild to moderate 
hypertriglyceridemia (TG 150–400 mg/dL), the 
combination of a statin and a fibrate is not usually 
recommended for reduction of cardiovascular 
risk. However, in the specific situation of a patient 
with triglycerides >204 mg/dL and HDL‑c < 34 mg/dL, the 
combination of fenofibrate and a statin can be considered 
when lifestyle modifications have failed. [IIa, B]
Summary of evidence
  • The pre-specified subgroup analysis of patients with 
diabetes from the ACCORD-LIPID (action to con-
trol cardiovascular risk in diabetes-lipids arm) study 
[129], comparing micronized fenofibrate 160 mg plus 
simvastatin 20–40  mg versus simvastatin 20–40  mg 
alone plus fenofibrate placebo, showed no reduction 
in the primary outcome. However, there was ben-
efit in the pre-specified subgroup analysis of patients 
with triglycerides >204 mg/dL and HDL-c < 34 mg/
dL.
  • The FIELD (fenofibrate intervention and event low-
ering in diabetes) multinational RCT, randomized 
9795 individuals with type 2 diabetes mellitus (aged 
50–75  years, 2131 with previous cardiovascular 
disease and 7664 without) not on statin treatment 
at study enrollment to receive micronized fenofi-
brate 200 mg daily (n =  4895) or matching placebo 
(n = 4900) for 5 years of follow up. The primary out-
come was coronary heart disease death or nonfatal 
myocardial infarction. The pre-specified outcome for 
subgroup analyses was total cardiovascular events 
(the composite of cardiovascular death, myocardial 
infarction, stroke, and coronary and carotid revas-
cularization). Fenofibrate did not reduce risk of the 
primary outcome. However, it reduced the secondary 
pre-specified outcome of total cardiovascular events, 
due to fewer nonfatal myocardial infarctions and 
revascularizations [130].
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Module 6. Management of hypertension
Targets
44. In patients with diabetes without clinical 
atherosclerotic disease (CLAD), blood pressure targets of a 
systolic blood pressure (SBP) < 130 mmHg and a diastolic 
blood pressure (DBP) < 80 mmHg may be reasonable, 
if well tolerated by the patient. [IIb, B]
Summary of evidence
  • In the ACCORD study [131] of 4733 diabetic 
patients, randomization to an SBP target <120 mmHg 
vs. <140  mmHg could not reduce significantly the 
risk of the study’s primary outcome (HR 0.88, 95% 
CI 0.73–1.06, p = 0.20). Thus, the results of the study 
do not support the recommendations for stricter 
BP targets in this patient population. The mean SBP 
achieved in the first year of treatment in this trial 
were 119.3  mmHg for the <120  mmHg arm and 
133.5  mmHg for the 140  mmHg arm, respectively. 
However, in the SBP  <  120  mmHg arm, there was 
a 41% reduction in risk of stroke (HR 0.59, 95% CI 
0.39–0.89, p = 0.01) with a low incidence of adverse 
events.
  • The ACCORD BP study used a 2 × 2 factorial design, 
which also included comparisons of standard or 
intensive glycemic targets combined with intensive 
or standard blood pressure control in the same trial. 
A secondary pre-specified analysis [132] showed that, 
when combining intensive glycemic control with 
intensive blood pressure control, the rate of major 
CVD outcomes was significantly lowered when com-
pared with combined standard BP and standard gly-
cemic control.
  •   In a network meta-analysis including 42 clinical trials 
with random allocation into anti-hypertensive medi-
cation, control, or treatment target, a total of 144,220 
individuals were compared in different strata of sys-
tolic blood pressure (SBP) to define the best target 
to reduce cardiovascular disease and all-cause mor-
tality. In 30 trials, patients with type 2 diabetes were 
included. Patients were analyzed according to their 
mean achieved SBP in nine strata: 120–124; 125–129; 
130–134; 135–139; 140–144; 145–149; 150–154; 
154–159; and >160 mmHg. There were linear associa-
tions between mean achieved SBP and the risk of car-
diovascular disease and mortality, with the lowest risk 
in the lowest stratum (120–124  mmHg). Individuals 
who achieved SBP 120–124 mmHg had a HR for all-
cause mortality of 0.73 (95% CI 0.58–0.93) compared 
to those in the SBP 130–134 mmHg stratum: HR 0.59 
(95% CI 0.45–0.77). Thus, reducing SBP levels to below 
130 mmHg is associated with significant reductions in 
cardiovascular disease and in all-cause mortality [133].
45. In patients with established coronary heart disease 
(CLAD), it is not recommended to reduce blood pressure 
below 120/70 mmHg. [III, B]
Summary of evidence
  • Because coronary perfusion occurs mainly during 
diastole, patients with coronary artery disease (CAD) 
could be at increased risk for coronary events if DBP 
falls below critical levels. A secondary analysis of data 
from the International Verapamil-Trandolapril Study 
(INVEST), including 22,576 patients with hyperten-
sion and CAD, determined whether low blood pres-
sure could be associated with excess mortality and 
morbidity in this population. The analysis found 
a progressive increase for the risk for the primary 
outcome, all-cause death, and MI, but not stroke, 
with low DBP. The authors concluded that excessive 
reduction in diastolic pressure should be avoided in 
patients with CAD who are being treated for hyper-
tension [134].
  • Data from 22,672 patients with stable coronary artery 
disease from 45 countries enrolled in the CLARIFY 
registry and treated for hypertension were analyzed 
to ascertain whether a relationship exists between 
achieved blood pressure rates and cardiovascular 
events. SBP and DBP before each event were aver-
aged and categorized into 10-mmHg increments. 
The primary outcome was a composite of cardiovas-
cular death, MI, or stroke. Hazard ratios (HR) were 
estimated with multivariable adjusted Cox propor-
tional hazards models, using 120–129  mmHg SBP 
and 70–79  mmHg DBP subgroups as references. 
The study concluded that, in patients with hyperten-
sion and coronary artery disease from routine clini-
cal practice, SBP < 120 mmHg and DBP < 70 mmHg 
were each associated with adverse cardiovascular 
outcomes, including mortality, supporting the exist-
ence of a J-curve phenomenon. Thus, caution is 
advised in the use of antihypertensive treatment in 
patients with coronary artery disease [135].
  • The ARIC (Atherosclerosis Risk In Communi-
ties) cohort of 11,565 adults analyzed associations 
between DBP and high-sensitivity cardiac troponin 
T (hs-cTnT) levels, as well as prospective asso-
ciations between DBP and CV events. Compared 
with persons who had DBP 80–89  mmHg at base-
line (ARIC visit 2), the adjusted odds ratio of hav-
ing hs-cTnT ≥  14 ng/L at that visit was 2.2 and 1.5 
in those with DBP  <  60  mmHg and 60–69  mmHg, 
respectively. Low DBP at baseline was also inde-
pendently associated with progressive myocardial 
damage on the basis of estimated annual change in 
hs-cTnT over the 6 years between ARIC visits 2 and 
4. In addition, compared with a DBP of 80–89  mm 
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Hg, a DBP < 60 mmHg was associated with incident 
CHD and mortality, but not with stroke. The DBP 
and incident CHD association was strongest with 
baseline hs-cTnT ≥ 14 ng/L (p value for interaction 
<0.001). Associations of low DBP with prevalent 
hs-cTnT and incident CHD were most pronounced 
among patients with baseline SBP  ≥  120  mmHg. 
The study concluded that, among adults with an 
SBP  ≥  120  mmHg (and, thus, elevated pulse pres-
sure), low DBP was associated with subclinical myo-
cardial damage and CHD events. When titrating 
treatment to SBP < 140 mmHg, it may be prudent to 
ensure that DBP levels do not fall below 70  mmHg 
and, particularly, not below 60 mmHg [136].
46. In patients with diabetes aged 80 years or older, a 
systolic blood pressure target <150 mmHg is reasonable. 
[IIa, B]
Summary of evidence
  • In the hypertensive elderly (age  ≥  80  years), there 
is no evidence of benefits deriving from BP levels 
<140 mmHg, but there is an increased likelihood of 
adverse effects. The HYVET Study supports the rec-
ommendation of a BP target <150/90  mmHg, with 
a reduction in the risk of stroke and HF [137, 138]. 
The presence of isolated systolic hypertension (ISH) 
requires care regarding excessive reduction in DBP, 
which should be maintained over 60 mmHg or even 
over 65 mmHg in the presence of CAD [139].
  • The SPRINT study reported a 24% reduction in the 
risk of the study’s primary outcome in elderly patients 
(age ≥75  years) allocated to the more intense BP 
treatment arm (mean SBP achieved, 123.4  mmHg) 
as compared to the group of standard SBP reduction 
(mean BP achieved, 134.8  mmHg). This occurred 
regardless of degree of fragility, with no increase in 
the number of adverse events in relation to the rest of 
the study population [140]. That suggests that BP tar-
gets for the elderly should be defined in the same as 
for other adults. It should be noted, however, that BP 
reduction should be performed carefully, considering 
comorbidities and the use of multiple medications.
47. In patients with stage III hypertension (defined 
as blood pressure ≥180/110 mmHg), the initial target 
blood pressure should be <140/90 mmHg. [I, A]
Summary of evidence
  • In a meta-analysis, Thomopoulos et  al. investigated 
if treatment to lower blood pressure benefits all 
grades of hypertension and determined the target BP 
levels to maximize outcome reduction. Significant 
outcome reductions were found independently of 
hypertension grade. No trend was observed toward 
changes in risk ratio with increasing baseline BP. In 
32 RCTs (128,232 individuals), relative and absolute 
outcome reductions were significant for the SBP dif-
ferences across 150 and 140  mmHg cutoffs. Below 
130 mmHg, only stroke and all-cause mortality were 
significantly reduced. There was a significant trend 
toward greater absolute outcome reduction with 
lower SBP cutoffs. In 29 RCTs (107,665 individuals), 
outcomes were significantly reduced across DBP cut-
offs of 90 and 80 mmHg. After excluding RCTs with 
baseline DBP <90  mmHg, only stroke reduction was 
significant at achieved DBP <80  mmHg. In conclu-
sion, meta-analyses favor BP-lowering treatment in 
all grades of hypertension, at low-to-moderate risk, 
and lowering SBP/DBP to less than 140/90  mmHg. 
Achieving <130/80  mmHg appears safe, but only 
adds further reduction in stroke [141].
48. In patients with diabetes and increased albuminuria 
(>30 mg/g of creatinine), it is recommended that systolic 
blood pressure and diastolic blood pressure targets should 
be <130 and <80 mmHg respectively. [I, A]
Summary of evidence
  • In the ADVANCE randomized clinical trial [142], 
11,140 patients with type 2 diabetes and hyperten-
sion were randomized to receive with a fixed com-
bination of perindopril and indapamide or matching 
placebo, in addition to current therapy. The primary 
endpoints were composites of major macrovascular 
and microvascular events (death from cardiovascu-
lar disease, nonfatal stroke, or nonfatal myocardial 
infarction) and new or worsening renal or diabetic 
eye disease. Analysis was by intention-to-treat. The 
macrovascular and microvascular composites were 
analyzed jointly and separately. Patients assigned 
to active therapy had a mean SBP reduction of 
5.6 mmHg and a mean DBP reduction of 2.2 mmHg 
compared to the placebo arm. The relative risk of a 
major macrovascular or microvascular event was 
reduced by 9% (861 [15.5%] active vs. 938 [16.8%] 
placebo; HR 0.91, 95% CI 0.83–1.00, p =  0.04). The 
separate reductions in macrovascular and micro-
vascular events were similar, but not independently 
significant (macrovascular: 0.92, 0.81–1.04, p = 0.16; 
microvascular: 0.91, 0.80–1.04, p = 0.16).
  • In the IRMA-2 multinational, double-blind RCT, 
590 hypertensive patients with type 2 diabetes and 
microalbuminuria were enrolled to receive irbesartan 
150 mg daily or 300 mg daily for 2 years. The primary 
outcome was time to onset of diabetic nephropa-
thy, defined by persistent albuminuria in overnight 
specimens, with a urinary albumin excretion rate 
>200 mcg/min and at least 30% higher than the 
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baseline level. Ten of the 194 patients in the 300-mg 
group (5.2%) and 19 of the 195 patients in the 150-
mg group (9.7%) reached the primary endpoint, as 
compared with 30 of the 201 patients in the placebo 
group (14.9%) (HR 0.30, 95% CI 0.14–0.61, p < 0.001, 
and HR 0.61, 95% CI 0.34–1.08, p  =  0.081 for the 
two irbesartan groups, respectively). The average 
blood pressure during the course of the study was 
144/83 mmHg in the placebo group, 143/83 mmHg 
in the 150-mg group, and 141/83 mmHg in the 300-
mg group (p =  0.004 for the comparison of systolic 
blood pressure between the placebo group and the 
combined irbesartan groups) [143].
Treatment
49. The choice of initial drug therapy for hypertension 
should be based on efficacy, tolerability, cost, and presence 
of comorbidities. In general, diuretics, ACE inhibitors, 
angiotensin receptor blockers, or calcium channel blockers 
can be useful as initial monotherapy. [IIa, B]
Summary of evidence
  • The randomized, double-blind, active-controlled 
antihypertensive and lipid-lowering treatment to 
prevent heart attack trial (ALLHAT), conducted 
from February 1994 through March 2002, evaluated 
33,357 participants (age ≥  55  years) with hyperten-
sion and at least one additional CHD risk factor from 
623 North American centers to determine if calcium 
channel blockers or angiotensin-converting enzyme 
(ACE) inhibitors would lower the incidence of CHD 
or other CV events vs. treatment with a diuretic. The 
primary outcome was combined fatal CHD or non-
fatal myocardial infarction, analyzed by intention to 
treat. Secondary outcomes were all-cause mortality, 
stroke, combined CHD (primary outcome, coro-
nary revascularization, or angina with hospitaliza-
tion), and combined CVD (combined CHD, stroke, 
treated angina without hospitalization, heart failure, 
and peripheral arterial disease). The primary out-
come occurred in 2956 participants, with no differ-
ence between treatments. Compared with chlorta-
lidone (6-year rate, 11.5%), the relative risks (RRs) 
were 0.98 (95% CI 0.90–1.07) for amlodipine (6-year 
rate, 11.3%) and 0.99 (95% CI 0.91–1.08) for lisinopril 
(6-year rate, 11.4%). Likewise, all-cause mortality did 
not differ between groups. For amlodipine vs. chlo-
rtalidone, secondary outcomes were similar except 
for a higher 6-year rate of heart failure with amlodi-
pine (10.2% vs. 7.7%; RR, 1.38; 95% CI 1.25–1.52). 
For lisinopril vs. chlortalidone, lisinopril had higher 
6-year rates of combined CVD (33.3% vs. 30.9%; RR, 
1.10; 95% CI 1.05–1.16); stroke (6.3% vs. 5.6%; RR, 
1.15; 95% CI 1.02–1.30); and HF (8.7% vs. 7.7%; RR, 
1.19; 95% CI 1.07–1.31) [144].
  • An analysis of the ALLHAT study to determine if 
treatment with a calcium channel blocker or an ACE 
inhibitor would decrease clinical complications com-
pared with treatment with a thiazide-type diuretic in 
DM, IFG, and normoglycemia provided no evidence 
of superiority for treatment with calcium channel 
blockers or ACE inhibitors compared with a thi-
azide-type diuretic during first-step antihypertensive 
therapy in these populations [145].
  • A meta-analysis of 354 randomized, double-blind, 
placebo-controlled trials of thiazides, beta blockers, 
ACE inhibitors, angiotensin II receptor antagonists, 
and calcium channel blockers in fixed dose was per-
formed. Placebo adjusted reductions in systolic and 
diastolic blood pressure and prevalence of adverse 
effects, according to dose expressed as a multiple 
of the standard (recommended) doses of the drugs, 
were the main outcomes. All five classes produced 
similar reductions in blood pressure, with aver-
age SBP and DBP reductions of 9.1 and 5.5  mmHg 
respectively at standard doses and 7.1 and 4.4 mmHg 
respectively (20% lower) at half-standard doses. The 
drugs reduced blood pressure from all pretreatment 
levels, more so from higher levels; for a 10  mmHg-
higher blood pressure, the reduction was 1.0 mmHg 
greater in SBP and 1.1  mmHg greater in DBP. The 
BP-lowering effects of different drug classes were 
additive. In addition, combination low-dose treat-
ment increased efficacy and reduced adverse effects. 
From the average blood pressure in people who have 
strokes (150/90  mmHg), three drugs at half-stand-
ard dose were estimated to lower blood pressure by 
20  mmHg systolic and 11  mmHg diastolic, thereby 
reducing the risk of stroke by 63% and the risk of 
ischemic heart disease events by 46% in the 60–69 
age range [146].
50. In patients with diabetes and urinary albumin 
>30 mg/g, treatment with ACE inhibitors or angiotensin 
receptor blockers are indicated. [I, A]
Summary of evidence
  • The reduction in end points in noninsulin-dependent 
diabetes mellitus with the angiotensin II antagonist 
losartan (RENAAL) study [147] investigated if albumi-
nuria, a marker of renal disease, could also be a moni-
tor of the renoprotective efficacy of RAS intervention 
by the angiotensin II (Ang II) antagonist losartan in 
patients with diabetic nephropathy. Data from the a 
double-blind randomized RENAAL trial were used 
to examine the effects of losartan on a renal outcome 
(primary composite endpoint of doubling of serum 
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creatinine, end-stage renal disease, or death) in 1513 
type 2 diabetic patients with nephropathy. The effect 
of the degree of albuminuria at baseline, initial anti-
proteinuric response to therapy, and the degree of 
residual albuminuria on renal outcome (either the pri-
mary composite end point of RENAAL or ESRD) were 
examined, as well as the contribution to renal protec-
tion of the antiproteinuric effect of losartan indepen-
dently of changes in blood pressure. Albuminuria was 
the predominant renal risk marker in patients with 
type 2 diabetic nephropathy on conventional treat-
ment; the higher the albuminuria, the greater the renal 
risk. Reduction in albuminuria was associated with a 
proportional effect on renal protection; the greater the 
reduction, the greater the renal protection. Residual 
albuminuria while on therapy (month 6) was consid-
ered as a strong marker of renal outcome, as was base-
line albuminuria. The antiproteinuric effect of losartan 
explained a major component of its specific renopro-
tective effect. Reduction of residual albuminuria to the 
lowest achievable level should be viewed as a goal for 
renoprotective treatments.
  • The Irbesartan Diabetic Nephropathy Trial addressed 
whether associations between baseline proteinuria and 
proteinuria reduction by either irbesartan, amlodipine, 
or control for similar decrements in blood pressure 
would be related to the cumulative incidence of renal 
endpoints. The risk of kidney failure doubled for each 
doubling of baseline proteinuria level (HR 2.04, 95% CI 
1.87–2.22, p < 0.001). For each halving of proteinuria 
level between baseline and 12  months on treatment, 
risk of kidney failure was reduced by more than half 
(HR 0.44, 95% CI 0.40–0.49, p < 0.001). The reduction 
in risk for kidney failure was significantly greater for 
irbesartan vs. amlodipine (p = 0.048), but not control 
(p = 0.245) for the same proportional change in pro-
teinuria. Proteinuria reduction in the first 12 months 
of therapy with irbesartan was associated with 36% 
of the total renoprotective effect observed. Proteinu-
ria reduction using an angiotensin receptor-blocking 
agent should be regarded as an important therapeutic 
goal for renoprotection [148].
  • The MICRO-HOPE study investigated whether the 
ACE inhibitor ramipril could lower risk of cardio-
vascular and renal disease in patients with diabetes 
[149]. A subset of 3577 people with diabetes included 
in the Heart Outcomes Prevention Evaluation study, 
aged 55  years or older, with a previous cardiovascu-
lar event or at least one other cardiovascular risk fac-
tor, no clinical proteinuria, heart failure, or low ejec-
tion fraction, and who were not taking ACE inhibitors 
were randomly assigned to receive ramipril (10  mg/
day) or placebo and vitamin E or placebo, according 
to a two-by-two factorial design. The combined pri-
mary outcome was myocardial infarction, stroke, or 
CV death. Overt nephropathy was a main outcome in 
a substudy. The study was interrupted 6 months ear-
lier (after 4.5 years) because of a consistent benefit of 
ramipril compared with placebo. Ramipril lowered the 
risk of the combined primary outcome by 25% (95% CI 
12–36, p = 0.0004), myocardial infarction by 22% (95% 
CI 6–36), stroke by 33% (95% CI 10–50), CV death by 
37% (95% CI 21–51), total mortality by 24% (95% CI 
8–37), revascularization by 17% (95% CI 2–30), and 
overt nephropathy by 24% (95% CI 3–40, p = 0.027). 
After adjustment for changes in SBP (2.4 mmHg) and 
DBP (1.0 mmHg), ramipril still lowered the risk of the 
combined primary outcome by 25% (95% CI 12–36, 
p = 0.0004). Ramipril was beneficial for cardiovascular 
events and overt nephropathy in people with diabetes. 
The study concluded that cardiovascular benefit was 
greater than that attributable to the decrease in blood 
pressure, thus representing a vasculoprotective and 
renoprotective effect for people with diabetes.
51. When using more than one antihypertensive to achieve 
target blood pressure, it is reasonable to combine either an 
ACE inhibitor or an ARB with a dihydropyridine calcium 
channel blocker. [IIa, B]
Summary of evidence
  • The ACCOMPLISH (Avoiding Cardiovascular 
Events Through COMbination Therapy in Patients 
Living With Systolic Hypertension) substudy [150], 
was designed to determine which combination ther-
apy in patients with hypertension and diabetes most 
effectively decreased cardiovascular events. The out-
comes effects of the ACE inhibitor benazepril, com-
bined with amlodipine (B+A) or hydrochlorothiazide 
(B+H), were analyzed separately in diabetic patients 
as a pre-specified endpoint. A total of 6946 patients 
with diabetes were randomized to treatment with 
B+A or B+H. A subgroup of 2842 diabetic patients 
at very high risk (previous CV events or stroke) was 
also analyzed, as were 4559 patients without diabe-
tes. The primary endpoint was a composite of car-
diovascular death, myocardial infarction, stroke, 
hospitalization for angina, resuscitated arrest, and 
coronary revascularization. In the full diabetes group, 
the mean achieved blood pressures in the B+A and 
B+H groups were 131.5/72.6 and 132.7/73.7 mmHg 
respectively; over 30  months of follow-up, there 
were 307 (8.8%) and 383 (11.0%) primary events (HR 
0.79, 95% CI 0.68–0.92, p = 0.003). For the diabetic 
patients at very high risk, there were 195 (13.6%) and 
244 (17.3%) primary events (HR 0.77, 95% CI 0.64–
0.93, p =  0.007). In the non-diabetic patients, there 
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were 245 (10.8%) and 296 (12.9%) primary events 
(HR 0.82, 95% CI 0.69–0.97, p =  0.020). In the dia-
betic patients, B+A therapy had clear coronary ben-
efits on both acute clinical events (p  =  0.013) and 
revascularizations (p =  0.024). In patients with dia-
betes and hypertension, the calcium channel blocker 
amlodipine is superior to the diuretic hydrochlo-
rothiazide when added to a renin-angiotensin sys-
tem blocker for reduction of cardiovascular events 
in patients with diabetes requiring management of 
hypertension.
52. A combination of 3 or more drugs (ACE inhibitor or 
ARB plus amlodipine and a thiazide diuretic) can be useful 
in achieving BP goals. [IIa, B]
Summary of evidence
  • A meta-analysis by Psaty [151] summarized the avail-
able clinical trial evidence concerning the safety 
and efficacy of various antihypertensive therapies 
used as first-line agents in terms of major cardio-
vascular disease endpoints and all-cause mortality. 
Network meta-analysis was used to combine direct 
within-trial between-drug comparisons with indi-
rect evidence from other trials. Indirect comparisons 
preserving within-trial randomized findings were 
constructed from trials that had one treatment in 
common. Data were combined from 42 clinical tri-
als that included 192,478 patients randomized to 7 
major treatment strategies, including placebo. For 
all outcomes, low-dose diuretics were superior to 
placebo for coronary heart disease (CHD; RR 0.79, 
95% CI 0.69–0.92); congestive heart failure (CHF; 
RR 0.51, 95% CI 0.42–0.62); stroke (RR 0.71, 95% CI 
0.63–0.81); CV events (RR 0.76, 95% CI 0.69–0.83); 
CV mortality (RR 0.81, 95% CI 0.73–0.92); and total 
mortality (RR 0.90, 95% CI 0.84–0.96). None of the 
first-line treatment strategies—beta blockers, ACE 
inhibitors, calcium channel blockers (CCBs), alpha 
blockers, and angiotensin receptor blockers—was 
significantly better than low-dose diuretics for any 
outcome. Compared with CCBs, low-dose diuretics 
were associated with reduced risks of CV events (RR 
0.94, 95% CI 0.89–1.00) and CHF (RR 0.74, 95% CI 
0.67–0.81). Compared with ACE inhibitors, low-dose 
diuretics were associated with reduced risks of CHF 
(RR 0.88, 95% CI 0.80–0.96), CV events (RR 0.94, 
95% CI 0.89–1.00), and stroke (RR 0.86, 0.77–0.97). 
Compared with beta blockers, low-dose diuretics 
were associated with a reduced risk of CV events (RR 
0.89, 95% CI 0.80–0.98). Compared with alpha block-
ers, low-dose diuretics were associated with reduced 
risks of CHF (RR 0.51, 95% CI 0.43–0.60) and CV 
events (RR 0.84, 95% CI 0.75–0.93). Blood pressure 
changes were similar between comparison treat-
ments. Low-dose diuretics were the most effective 
first-line treatment for preventing the occurrence of 
CV-related morbidity and mortality.
53. A combination of an ACE inhibitor and an ARB or a 
renin blocker is NOT recommended, due to the greater risk 
of loss of renal function, syncope, and hyperkalemia. [III, A]
Summary of evidence
  • The ALTITUDE study asked whether the use of 
aliskiren would reduce cardiovascular and renal 
events in patients with type 2 diabetes and chronic 
kidney disease, cardiovascular disease, or both. 
The trial was stopped prematurely after the second 
interim efficacy analysis, because, after a median fol-
low-up of 32.9 months, the primary endpoint (com-
posite of the time to CV death or a first occurrence 
of cardiac arrest with resuscitation; nonfatal myo-
cardial infarction; nonfatal stroke; unplanned hospi-
talization for heart failure; end-stage renal disease, 
death attributable to kidney failure, or need for renal 
replacement therapy with no dialysis or transplanta-
tion available or initiated; or doubling of the serum 
creatinine level from baseline) had occurred in 783 
patients (18.3%) assigned to aliskiren as compared 
with 732 (17.1%) assigned to placebo (HR 1.08, 95% 
CI 0.98–1.20, p =  0.12). Thus, data do not support 
the addition of aliskiren to standard therapy with 
renin-angiotensin system blockade in patients with 
type 2 diabetes who are at high risk of cardiovascular 
and renal events. In fact, aliskiren may even be harm-
ful [152].
  • The ASTRONAUT study [153] was designed to 
investigate whether adding aliskiren to standard 
therapy would reduce the rate of CV death or read-
mission among HHF (hospitalization for heart fail-
ure) patients. Eligible patients were aged ≥18 years, 
with left ventricular ejection fraction (LVEF) 40% or 
less, elevated natriuretic peptides (brain natriuretic 
peptide [BNP] ≥ 400 pg/mL or N-terminal pro-BNP 
[NT-proBNP] ≥ 1600 pg/mL), and signs and symp-
toms of fluid overload. All patients received 150 mg 
of aliskiren (increased to 300 mg as tolerated) or pla-
cebo daily, in addition to standard therapy. The study 
drug was continued after discharge for a median 
11.3  months. The main outcome measures were 
CV death or HF rehospitalization at 6  months and 
12 months. In total, 1639 patients were randomized, 
with 1615 patients included in the final efficacy anal-
ysis cohort (808 aliskiren, 807 placebo). At randomi-
zation, patients were receiving diuretics (95.9%), beta 
blockers (82.5%), ACE inhibitors or ARBs (84.2%), 
and mineralocorticoid receptor antagonists (57.0%). 
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In total, 24.9% of patients receiving aliskiren (77 CV 
deaths, 153 HF readmissions) and 26.5% of patients 
receiving placebo (85 CV deaths, 166 HF readmis-
sions) experienced the primary endpoint at 6 months 
(HR 0.92, 95% CI 0.76–1.12, p = 0.41). At 12 months, 
the event rates were 35.0% for the aliskiren group 
(126 CV deaths, 212 HF readmissions) and 37.3% 
for the placebo group (137 CV deaths, 224 HF read-
missions; HR 0.93, 95% CI 0.79–1.09, p = 0.36). The 
rates of hyperkalemia, hypotension, and renal impair-
ment/failure were higher in the aliskiren group than 
in the placebo arm. Among patients hospitalized for 
HF with reduced LVEF, initiation of aliskiren in addi-
tion to standard therapy did not reduce CV death or 
HF readmission at 6 months or 12 months after dis-
charge.
  • In patients who have vascular disease or high-risk 
diabetes without heart failure, ACE inhibitors reduce 
mortality and morbidity from cardiovascular causes, 
but the role of ARBs in such patients is unknown. 
The ACE inhibitor ramipril, the ARB telmisartan, and 
a combination of the two drugs in patients with vas-
cular disease or high-risk diabetes were compared in 
the ONTARGET study [154]. A total of 8576 patients 
were assigned to receive 10  mg of ramipril per day, 
8542 were assigned to receive 80  mg of telmisar-
tan per day, and 8502 were assigned to receive both 
drugs. The primary composite outcome (death from 
cardiovascular causes, myocardial infarction, stroke, 
or hospitalization for heart failure) occurred in 16.5% 
of patients in the ramipril group, 16.7% in the tel-
misartan group, and 16.3% in the combined-therapy 
group (differences were not statistically significant). 
However, more adverse events were seen in patients 
randomized to combined therapy. In conclusion, the 
combination of the two drugs was associated with 
more adverse events, without increased benefit.
Module 7: Rationale for antiplatelet therapy
54. In patients with diabetes without clinical 
atherosclerotic disease (CLAD), i.e., in primary prevention, 
antiplatelet therapy is generally not recommended. [III, A]
Summary of evidence
  • Trials of antiplatelet therapy versus control included 
about 70,000 “high-risk” patients (with vascular dis-
ease or another condition implying an increased risk 
of occlusive vascular disease) and 30,000 “low-risk” 
subjects from the general population. Direct com-
parisons of different antiplatelet regimens involved 
about 10,000 high-risk patients. In each of four main 
high-risk categories, antiplatelet therapy was defi-
nitely protective. Among low-risk recipients of “pri-
mary prevention”, a significant, one-third reduction 
in nonfatal myocardial infarction was accompanied 
by a nonsignificant increase in stroke. The absolute 
reduction in vascular events was much smaller than 
for high-risk patients, despite a much longer treat-
ment period, and was not significant. There is no 
clear evidence on the balance of antiplatelet therapy 
in primary prevention among low-risk subjects [155].
  • A meta-analysis of randomized controlled trials was 
performed to evaluate the benefits and harms of low-
dose aspirin in people with diabetes and no cardio-
vascular disease. Six studies were eligible, with 10,117 
participants. When aspirin was compared with pla-
cebo, there was no statistically significant reduction 
in the risk of major CV events (five studies, n = 9584; 
RR 0.90, 95% CI 0.81–1.00), CV mortality (four 
studies, n  =  8557; RR 0.94, 95% CI 0.72–1.23), or 
all-cause mortality (four studies, n = 8557; RR 0.93, 
95% CI 0.82–1.05). There was significant heterogene-
ity in analysis for myocardial infarction  (I2 = 62.2%; 
p = 0.02) and stroke  (I2 = 52.5%; p = 0.08). Aspirin 
significantly reduced the risk of myocardial infarc-
tion in men (0.57, 0.34–0.94) but not in women (1.08, 
0.71–1.65; p value for interaction = 0.056). Evidence 
relating to harms was inconsistent [156].
55. In patients with diabetes without clinical 
atherosclerotic disease (Table 5) in the HIGH‑RISK category 
(Table 2), aged >65 years and with low risk of bleeding, 
acetylsalicylic acid can be useful. [IIa, B]
Summary of evidence
  • The Japanese Primary Prevention of Atherosclerosis 
with Aspirin for Diabetes (JPAD) trial was designed 
to examine the efficacy of low-dose aspirin for pri-
mary prevention of atherosclerotic events in patients 
with type 2 diabetes and no previous cardiovascular 
events. The study randomized 1262 patients to receive 
aspirin (81 mg or 100 mg) and 1277 patients to a non-
aspirin group. Mean (SD) age was 65 (10) years, and 
55% were men; 58% of patients had hypertension, 53% 
had dyslipidemia, and BP and HbA1c were well con-
trolled in both groups. The median follow-up period 
was 4.37 years and 193 patients were lost to follow-up, 
with data for those patients censored at the day of last 
follow-up. There was no reduction in the risk of CV 
events with low-dose aspirin for high-risk patients 
with diabetes in primary prevention. However, the 
event rate was lower than expected overall, and these 
findings should be interpreted in context with the low 
incidence of atherosclerotic disease in Japan and cur-
rent management of cardiovascular risk factors [157].
  • A sub-analysis from the JPAD study evaluating 
patients with diabetes divided according to SBP 
and DBP at enrollment (“target unattained” group, 
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SBP  ≥  140  mmHg and/or DBP  ≥  90  mmHg; 
“target attained” group, SBP  <  140  mmHg and 
DBP  <  90  mmHg) demonstrated that the incidence 
of the primary atherosclerotic events, especially cer-
ebrovascular events, was higher in the unattained 
group than in the attained group. The incidence of 
cerebrovascular events was higher in the unattained 
group than in the attained group in patients without 
aspirin therapy; however, the incidence of cerebrovas-
cular events in the unattained group was as low as the 
incidence in the attained group in patients on aspirin 
therapy. Cox proportional hazards analysis revealed 
that BP level was an independent predictor of cerebro-
vascular events in diabetic patients [158].
  • In a meta-analysis of RCTs with aspirin including 14 tri-
als (107,686 participants), aspirin was associated with 
reductions in major cardiovascular events (risk ratio 
0.90, 95% CI 0.85–0.95), myocardial infarction (risk 
ratio 0.86, 95% CI 0.75–0.93), ischemic stroke (risk 
ratio 0.86, 95% CI 0.75–0.98), and all-cause mortal-
ity (risk ratio 0.94, 95% CI 0.89–0.99). However, there 
were increases in hemorrhagic stroke (risk ratio 1.34, 
95% CI 1.01–1.79) and major bleeding (risk ratio 1.55, 
95% CI 1.35–1.78) with aspirin. The number needed 
to treat to prevent 1 major cardiovascular event over 
a mean follow-up of 6.8 years was 284. By comparison, 
the number needed to harm to cause 1 major bleed-
ing was 299. In subgroup analyses, pooled results 
demonstrated a reduction in myocardial infarction 
among men (RR 0.71, 95% CI 0.59–0.85) and ischemic 
stroke among women (RR 0.77, 95% CI 0.63–0.93). 
Aspirin use was associated with a reduction (RR 0.65, 
95% CI 0.51–0.82) in myocardial infarction among 
diabetic men. The results of meta-regression analyses 
suggested that aspirin therapy might be associated 
with a decrease in stroke among diabetic women and 
a decrease in MI among diabetic men, and that risk 
reductions achieved with low doses (75 mg/day) were 
as large as those obtained with higher doses (650 mg/
day). The study concluded that low-dose aspirin was 
beneficial for primary prevention of CVD, and that the 
decision regarding an aspirin regimen should be made 
on an individual patient basis. The effects of aspirin 
therapy varied by sex and diabetes status [159].
56. In VERY HIGH‑RISK patients, including those 
with clinical atherosclerotic disease (CLAD) and prior 
cardiovascular events (secondary prevention), antiplatelet 
therapy is indicated. [I, A]
Summary of evidence
  • A collaborative meta-analysis of randomized trials of 
an antiplatelet regimen versus control or of one anti-
platelet regimen versus another in high-risk patients 
(with acute or previous vascular disease or some 
other predisposing condition) was performed [6]. 
Trials had to use a randomization method that pre-
cluded prior knowledge of the next treatment to be 
allocated, and comparisons had to have study groups 
that differed only in terms of antiplatelet regimen. A 
total of 287 studies were included, involving 135,000 
patients in comparisons of antiplatelet therapy versus 
control and 77,000 in comparisons of different anti-
platelet regimens. Aspirin (or another oral antiplate-
let drug) was protective in most types of patient at 
increased risk of occlusive vascular events, including 
those with AMI or ischemic stroke, unstable or sta-
ble angina, previous MI, stroke or cerebral ischemia, 
peripheral arterial disease, or atrial fibrillation [160].
57. In VERY HIGH‑RISK patients with aspirin allergy or 
gastric intolerance, clopidogrel should be considered as an 
acceptable alternative. [IIa, B]
Summary of evidence
  • The Clopidogrel vs. Aspirin in Patients at Risk of 
Ischemic Events (CAPRIE) trial was a randomized, 
blinded, multicenter trial of 19,185 patients with ath-
erosclerotic disease manifested as recent ischemic 
stroke or myocardial infarction or symptomatic 
peripheral arterial disease. The number of readmis-
sions for ischemic events (defined as angina, tran-
sient ischemic attack, or limb ischemia) or bleed-
ing events was determined for the entire cohort. A 
significant reduction in the total number of read-
missions for ischemic events or bleeding was seen 
with clopidogrel use compared with aspirin (1502 
vs. 1673, p =  0.010) over an average of 1.6  years of 
treatment. This reduction in rehospitalization was 
consistent across individual outcomes of angina, 
transient ischemic attack, limb ischemia, and bleed-
ing. Clopidogrel also resulted in a 7.9% relative risk 
reduction in a combined endpoint of vascular death, 
stroke, myocardial infarction, or rehospitalization for 
ischemic events or bleeding (15.1–13.7% at 1  year, 
p = 0.011) as compared with aspirin [161].
58. Dual antiplatelet therapy is recommended for at least 
1 year in VERY HIGH‑RISK patients after acute coronary 
syndrome. [I, A]
Summary of evidence
  • The TRITON-TIMI 38 trial aimed to randomly com-
pare prasugrel (a new thienopyridine antiplatelet 
agent) vs. clopidogrel in 13,608 patients with mod-
erate-to-high-risk acute coronary syndromes sched-
uled to undergo percutaneous coronary intervention. 
Prasugrel was given in a 60-mg loading dose and a 
10-mg daily maintenance dose, while clopidogrel was 
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given as a 300-mg loading dose and a 75-mg daily 
maintenance dose, for 6–15  months. The primary 
efficacy endpoint was death from cardiovascular 
causes, nonfatal myocardial infarction, or nonfatal 
stroke. The key safety endpoint was major bleeding. 
The primary endpoint occurred in 12.1% of patients 
in the clopidogrel arm and 9.9% of patients receiving 
prasugrel (HR for prasugrel vs. clopidogrel, 0.81; 95% 
CI 0.73–0.90, p < 0.001). In the prasugrel group, there 
were significant reductions in rates of myocardial 
infarction (9.7% for clopidogrel vs. 7.4% for prasug-
rel, p < 0.001), urgent target-vessel revascularization 
(3.7% vs. 2.5%, p < 0.001), and stent thrombosis (2.4% 
vs. 1.1%, p < 0.001). Major bleeding was observed in 
2.4% of patients receiving prasugrel and in 1.8% of 
patients receiving clopidogrel (HR 1.32, 95% CI 1.03–
1.68, p  =  0.03). The rate of life-threatening bleed-
ing was higher in the prasugrel arm (1.4% vs. 0.9%, 
p = 0.01), including nonfatal (1.1% vs. 0.9%, HR 1.25, 
p = 0.23) and fatal bleeding (0.4% vs. 0.1%, p = 0.002) 
[162].
  • In the CURE study, 2658 patients with non-ST-ele-
vation acute coronary syndrome undergoing PCI 
were randomly assigned to double-blind treatment 
with clopidogrel (n =  1313) or placebo (n =  1345). 
Patients were pretreated with aspirin and clopi-
dogrel for a median of 6  days before PCI during 
the initial hospital admission, and for a median of 
10  days overall. After PCI, most patients (>80%) in 
both groups received open-label thienopyridine for 
about 4 weeks, after which clopidogrel was restarted 
for a mean of 8 months. The primary endpoint was 
a composite of cardiovascular death, myocardial 
infarction, or urgent target-vessel revasculariza-
tion within 30  days of PCI, in an intention-to-treat 
analysis. Fifty-nine (4.5%) patients in the clopidogrel 
group reached the primary endpoint, compared 
with 86 (6.4%) in the placebo group (RR 0.70, 95% 
CI 0.50–0.97, p  =  0.03). Long-term administration 
of clopidogrel after PCI was associated with a lower 
rate of CV death, myocardial infarction, or any revas-
cularization (p = 0.03) and of CV death or myocar-
dial infarction (p = 0.047). Overall, including events 
before and after PCI, there was a 31% reduction in 
CV death or myocardial infarction (p = 0.002), and, 
at follow-up, there was no significant difference in 
major bleeding between the groups (p = 0.64) [163].
  • In the CHARISMA trial, 15,603 patients with either 
clinically evident cardiovascular disease or multiple 
risk factors were randomized to receive clopidogrel 
(75  mg per day) plus low-dose aspirin (75–162  mg 
per day) or placebo plus low-dose aspirin and fol-
lowed for a median of 28  months. The primary 
endpoint was a composite of myocardial infarction, 
stroke, or death from cardiovascular causes. The rate 
of the primary efficacy endpoint was 6.8% with clopi-
dogrel plus aspirin and 7.3% with placebo plus aspirin 
(RR 0.93, 95% CI 0.83–1.05, p = 0.22). The principal 
secondary efficacy endpoint, which included hos-
pitalizations for ischemic events, occurred in 16.7% 
and 17.9% (RR 0.92, 95% CI 0.86–0.995, p  =  0.04), 
and the rate of severe bleeding was 1.7% and 1.3% 
(RR 1.25, 95% CI 0.97–1.61. p  =  0.09). In patients 
with multiple risk factors, the rate of the primary 
endpoint was 6.6% with clopidogrel and 5.5% with 
placebo (RR 1.2, 95% CI 0.91–1.59, p  =  0.20), and 
the rate of death from cardiovascular causes was also 
higher with clopidogrel (3.9% vs. 2.2%, p = 0.01). In 
subgroup analysis of patients with clinically evident 
atherothrombosis, the rate was 6.9% with clopidogrel 
and 7.9% with placebo (RR 0.88, 95% CI 0.77–0.998, 
p = 0.046), suggesting benefit with clopidogrel treat-
ment in patients with symptomatic atherothrombo-
sis and harm in patients with multiple risk factors. 
Overall, clopidogrel plus aspirin was not significantly 
more effective than aspirin alone in reducing the rate 
of myocardial infarction, stroke, or death from car-
diovascular causes [164].
  • In the multicenter, double-blind, randomized PLATO 
trial, ticagrelor (180-mg loading dose, 90  mg twice 
daily thereafter) and clopidogrel (300–600-mg load-
ing dose, 75 mg daily thereafter) were compared for 
the prevention of CV events in 18,624 patients admit-
ted to hospital with an acute coronary syndrome, 
with or without ST-segment elevation. At 12 months, 
the primary composite endpoint (death from vas-
cular causes, myocardial infarction, or stroke) had 
occurred in 9.8% of patients receiving ticagrelor as 
compared with 11.7% of those receiving clopidogrel 
(p < 0.001). The rate of death from any cause was also 
reduced with ticagrelor (4.5% vs. 5.9% with clopi-
dogrel, p  <  0.001). No significant difference in rates 
of major bleeding was found between the ticagre-
lor and clopidogrel groups (p = 0.43), but ticagrelor 
was associated with a higher rate of major bleeding 
not related to coronary-artery bypass grafting (4.5% 
vs. 3.8%, p = 0.03), including more instances of fatal 
intracranial bleeding and fewer of fatal bleeding of 
other types [165].
  • The PEGASUS study investigated the efficacy and 
safety of ticagrelor after an acute coronary syndrome, 
in a double-blind 1:1:1 fashion. The trial randomized 
21,162 patients who had had a myocardial infarc-
tion 1–3 years earlier to ticagrelor 90 mg twice daily, 
ticagrelor 60 mg twice daily, or placebo. All patients 
received low-dose aspirin and were followed for a 
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median of 33  months. The primary efficacy end-
point was the composite of cardiovascular death, 
myocardial infarction, or stroke. The primary safety 
endpoint was Thrombolysis in Myocardial Infarc-
tion (TIMI)-defined major bleeding. Both ticagrelor 
doses reduced the rate of the primary efficacy end-
point, with Kaplan–Meier rates at 3  years of 7.85% 
in the 90-mg ticagrelor group, 7.77% in the 60-mg 
ticagrelor group, and 9.04% in the placebo group 
(HR for 90-mg ticagrelor vs. placebo: 0.85, 95% CI 
0.75–0.96, p  =  0.008; HR for 60-mg ticagrelor vs. 
placebo: 0.84, 95% CI 0.74–0.95, p  =  0.004). Rates 
of TIMI major bleeding were higher with ticagrelor 
(2.60% with 90 mg and 2.30% with 60 mg) than with 
placebo (1.06%) (p < 0.001 for each dose vs. placebo); 
the rates of intracranial hemorrhage or fatal bleeding 
in the three groups were 0.63, 0.71, and 0.60% respec-
tively. Therefore, in patients with a previous myocar-
dial infarction at least 1 year before, treatment with 
ticagrelor significantly reduced the risk of CV death, 
myocardial infarction, and stroke, but increased the 
risk of major bleeding [166].
59. In patients who are not at high risk of bleeding 
complications, continuation of dual antiplatelet therapy 
may be reasonable for longer than 12 months after acute 
coronary syndrome. [IIb, A]
Summary of evidence
  • In the PEGASUS study, the efficacy and safety of tica-
grelor after an acute coronary syndrome was inves-
tigated in a double-blind 1:1:1 fashion. The trial ran-
domized 21,162 patients who had had a myocardial 
infarction 1–3 years earlier to ticagrelor at a dose of 
90 mg twice daily, ticagrelor at a dose of 60 mg twice 
daily, or placebo. All the patients received low-dose 
aspirin and were followed for a median of 33 months. 
The primary efficacy endpoint was the composite 
of cardiovascular death, myocardial infarction, or 
stroke. The primary safety endpoint was Thromboly-
sis in Myocardial Infarction (TIMI) major bleeding. 
Ticagrelor in both doses reduced the rate of the pri-
mary efficacy endpoint, with Kaplan–Meier rates at 
3 years of 7.85% in the group receiving 90 mg of tica-
grelor twice daily, 7.77% in the group receiving 60 mg 
of ticagrelor twice daily, and 9.04% in the placebo 
group (hazard ratio for 90  mg of ticagrelor vs. pla-
cebo, 0.85; 95% CI 0.75–0.96; p = 0.008; hazard ratio 
for 60 mg of ticagrelor vs. placebo, 0.84; 95% CI 0.74–
0.95; p = 0.004). Rates of TIMI major bleeding were 
higher with ticagrelor (2.60% with 90 mg and 2.30% 
with 60  mg) than with placebo (1.06%) (p  <  0.001 
for each dose vs. placebo); the rates of intracranial 
hemorrhage or fatal bleeding in the three groups 
were 0.63, 0.71, and 0.60% respectively. Therefore, 
in patients with a previous myocardial infarction, at 
least one year earlier, treatment with ticagrelor sig-
nificantly reduced the risk of cardiovascular death, 
myocardial infarction, or stroke, and increased the 
risk of major bleeding [166]. The DAPT study sought 
to investigate if 30  months of DAPT was superior 
to 12 months in patients undergoing DES and bare-
metal stent (BMS) PCI. A total of 9961 patients were 
randomized at 452 sites in 11 countries: 5020 to pro-
longed DAPT and 4941 to placebo. Approximately 
30% had diabetes mellitus, 25% were smokers and 6% 
had peripheral arterial disease. Patients were enrolled 
72  h after stent placement and were given open-
label aspirin and thienopyridine for 12  months, per 
current practice norms. Indication for PCI was sta-
ble angina in 38%, ST-segment elevation myocardial 
infarction (STEMI) in 10% and NSTE-acute coronary 
syndrome (NSTE-ACS) in 32%. Approximately two-
thirds of the patients received clopidogrel, whereas 
the rest received prasugrel. At 12  months, patients 
without an ischemic or bleeding complication and 
with documented compliance, were randomized 
in a 1:1 fashion to receive an additional 18  months 
of DAPT or matching placebo. The primary end-
point of major adverse cardiac and cerebrovascu-
lar events (MACCE) was significantly lower in the 
continued DAPT arm compared with placebo (4.3% 
vs. 5.9%, hazard ratio 0.71, 95% confidence interval 
0.59–0.85, p  <  0.001). There were reductions in all 
MI (2.1% vs. 4.1%, p  <  0.001) and stent thrombosis 
(0.4% vs. 1.4%, p < 0.001), but all-cause mortality was 
higher (2.0% vs. 1.5%, p = 0.05), driven mostly by an 
increase in non-cardiovascular deaths (1% vs. 0.5%, 
p = 0.002), including cancer-related death (0.62% vs. 
0.28%, p  =  0.02) and bleeding-related death (0.22% 
vs. 0.06%, p  =  0.06). Moderate and severe GUSTO 
bleeding was also higher with DAPT (2.5% vs. 1.6%, 
p =  0.001), as was BARC 2, 3, or, 5 bleeding (5.6% 
vs. 2.9%, p  <  0.001). The DAPT study showed that 
longer duration of DAPT following PCI results in 
lower stent thrombosis and recurrent MIs, but higher 
bleeding and all-cause mortality compared with a 
12-month duration [167].
Conclusions
Although cardiovascular risk is increased in patients 
with diabetes when compared to age-matched nondia-
betic individuals, recent evidence indicates that there is 
a high prevalence of lower-risk individuals among this 
population. Risk stratification is clearly needed, either 
to intensify more effective preventive measures in high-
risk categories or to avoid overtreatment of lower-risk 
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patients. The present Panel structured a risk-based guide 
to help clinicians optimize cardiovascular prevention in 
diabetes. The Panel recovered the concept of treating-to-
target, as they are considered important to promote bet-
ter adhesion to treatment and can be useful for clinicians 
to improve prevention in clinical practice. In the present 
guideline, there is a clear shift toward a  more inten-
sive treatment in the very-high risk category, especially 
regarding lipid-lowering therapy with statins, where new, 
lower lipid targets are proposed. The Panel understands 
that patients with diabetes at very high risk have very 
high mortality and one of the most important currently 
available actions to reduce residual risk is to obtain fur-
ther reductions in LDL-c levels. The panel also reviews 
the potential role of the new anti-hyperglycemic drugs 
in reducing cardiovascular risk, as well as hypertension 
targets and drug choice. Finally, we also propose a prac-
tical guideline to guide decision-making about screening 
for silent coronary artery disease. We understand that 
intensifying treatment may increase costs to the health 
care system; however, the number of avoided events and 
lives saved clearly outweighs these costs. The Brazilian 
Diabetes Society, the Brazilian Cardiology Society, and 
the Brazilian Endocrinology Society are now united in 
the task to reduce cardiovascular disease in patients with 
diabetes.
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